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by
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ABSTRACT
The purpose of this study was to examine Georgia physicians’ administration of the
quadrivalent human papillomavirus (HPV) vaccine to 11-12 year old females according
to the Advisory Council Immunization Practices (ACIP) guidelines, their intention to
recommend HPV vaccine to 11-12 year old males, and their perceived knowledge and
barriers associated with HPV vaccination. A distinction between urban and rural was
examined to determine if there were differences in HPV vaccination recommendation. A
stratified sample was created from the Georgia Vaccine For Children (VFC) provider list.
The final sampling frame included 264 (n = 264) providers. Of these, 218 physicians
were contacted yielding a response rate of 82.6%. Forty-two were located in rural
counties and 176 were located in urban counties. Examination of perceived barriers,
perceived knowledge and administration practices revealed no differences between urban
and rural physicians. Approximately one in ten Georgia physicians (12%) who
responded reported they always vaccinate 11-12 year old females. The number increased
to one in five (22.9%) who always vaccinate females age 13-17 years, suggesting parents
or physicians may be delaying vaccination until females are older than 12 years.

Approximately one quarter (23.7%) recommend the vaccine to their male patients. More
than half (59.4%) reported insufficient insurance coverage for the vaccine as a barrier to
vaccinating males and females. In multivariate logistic regression models, variables
independently associated with not recommending to 11-12 year old females included:
female gender of the physician (OR, 3.07; 95% CI, 1.02-9.29) and parental barriers (OR
1.15; CI, 1.04-1.29). There were no associated findings with not recommending male
vaccination. Findings from this study may serve as a helpful resource for further
assessment of HPV vaccination in Georgia and targeting educational and policy
interventions.
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CHAPTER 1
BACKGROUND SIGNIFICANCE AND LITERATURE REVIEW
Introduction
The human papillomavirus (HPV) is the most common sexually transmitted virus in the
United States and it is estimated that 70% of sexually active men and women acquire an
infection at some point during their lifetime (CDC, 2010). In total numbers, approximately 20
million people in the United States are currently infected with 6.2 million new infections
annually (Dunne & Markowitz, 2006). Using census figures (Census Bureau 2010) for Georgia
(n= 9,829,211), approximately 633,000 people in are Georgia currently infected with genital
HPV, and approximately 20,000 people in Georgia will acquire a new genital HPV infection
each year.
In the majority of people, HPV infections are not serious. Most infections are
asymptomatic, transient, and resolve without medical intervention. While an HPV infection is
necessary for the development of precursor lesions and cervical cancer, it is not always sufficient
to cause cervical abnormalities (CDC, 2010). However, continuous infection of one or more
high-risk HPV types, particularly subtypes 16 and 18, can result in precursor lesions and cervical
cancer (Muñoz et al., 2003). Approximately 11,000 cases of cervical cancer occur in the United
States annually. Of these 11,000 cases, approximately 36.4% will result in death (NCI, 2010).
Cervical cancer also causes and economic burden and it is estimated that over $2 billion dollars
is spent annually on the treatment of cervical cancer in the United States (CDC, 2010).
Estimates for the incidence and prevalence of genital warts caused by low-risk HPV types 6
and 11 are inexact. However, it is estimated that 5.6% of sexually active adults age 18 to 59
years living in the United States report ever being diagnosed with genital warts (Dinh, Dunne, &
1

Markowitz, 2008). According to the Centers for Disease Control and Prevention (CDC), there
are approximately one million new cases of genital warts each year in the United States (CDC,
2010).
Although genital warts are commonly perceived as a non-serious condition, treatment is
often lengthy with 25% of cases reoccurring within three months (Mandell, Bennett, & Dolin,
2009). Men and women who participated in a study by Mortensen (2010) considered quality of
life to be significantly lowered because of genital warts, and participants expressed negative
psychological and social effects. They also believed genital warts were associated with adverse
consequences of daily life and affect the ability to develop new relationships. Women who took
part in a study by McCaffery et al. (2006) described feeling stigmatized, anxious and stressed.
They were concerned about new relationships and worried about disclosing their condition to
others. This was also true regarding the psychological burden of the HPV infection and the
woman’s relationship status and history, their social and cultural norms and practices around sex
and relationships, as well as their understanding of key features of HPV (McCaffery, Waller,
Nazroo, & Wardle, 2006).
The burden of HPV infection and cervical cancer can be eliminated now that a vaccine
targeting the HPV virus has been developed. On June 8th, 2006, the U.S. Food and Drug
Administration (FDA) approved Gardasil® by Merck Pharmaceuticals as the first quadrivalent
HPV vaccine to protect women from HPV infection of subtypes 6, 11, 16, and 18 (Markowitz et
al., 2007). Less than one year later, in 2007, the Advisory Council on Immunization Practices
(ACIP) of the CDC recommended all girls aged 11 and 12 years be vaccinated against HPV,
with the indication that girls as young as 9 years of age, and older females between the ages of
13 and 26 may receive the vaccine at their providers’ discretion (Markowitz et al., 2007).
2

In order for the HPV vaccine to be most effective, it must be administered prior to onset of
sexual activity and the exposure to the HPV virus, which requires administering to preadolescents and young adolescents (Markowitz et al., 2007). Dempsey, Koutsky, and Golden
(2007) indicate HPV is “nearly ubiquitous among sexually active individuals….” (p.506) and
further note “… individuals do not need to engage in high-risk sexual behavior to become
infected.…” (p. 506) thus indicating the vaccine must be administered early rather than later if it
is to be effective.
In another study involving 60 adolescent women, 27% of a group of females were infected
with HPV. This increased to 45% for females aged 14 to 24, leading researchers to conclude that
the “cumulative prevalence of HPV infection in sexually active adolescent women is extremely
high” (Brown et al., 2005). Research by Hopenhayn, Christian, Christian, and Schoenberg
(2007), report one-third of Kentucky ninth graders admit to having sexual intercourse and twothirds report doing so by the time they are seniors in high school. Charo (2007) noted youth
dropout rates from school begin to increase after age 13 and youth who leave school are more
likely to engage in sexual activity earlier.
As we learn more about the early onset of sexual activity of adolescents and their increased
risk for HPV infection, it becomes apparent a vaccine protective of both males and females
would be beneficial if the virus is to be defeated. This is further noted as there is a high rate of
transmission of HPV in female partners of men with pre-existing genital warts, and HPV
infection in men has been shown to contribute to HPV infection and subsequent cervical disease
and cancer in women (MMWR, May, 2010). On October 16, 2009, the FDA approved the same
quadrivalent HPV vaccine, Gardasil®, for use in boys and men 9 through 26 years of age for the
prevention of genital warts caused by HPV subtypes 6 and 11. In addition, this vaccine offers
3

protection to their female partners against subtypes 6 and 11, making it the only HPV vaccine
approved for use in males (FDA, 2009).
Presently, there is debate on the cost effectiveness of the HPV vaccine and the potential for
herd immunity given that it has been recommended to both females and males. In a presentation
to the ACIP on October 21, 2009, a CDC Health Economist, Dr. Harrell Chesson, stated factors
associated with HPV vaccination cost effectiveness include protection against HPV subtypes 6,
11, 16, and 18, duration of protection, degree of cross protection, and vaccine price (Chesson,
2009). According to Chesson’s research, the possible reduction in the fifty million annual
cervical cytology (Pap) screens to detect cervical disease is an important benefit of HPV
vaccination (Chesson, 2009). In a 2011 report to the ACIP, Dr. Chesson noted 12 year old girls
who received the vaccine had a cost per quality-adjusted life year ranging from $3,000 to
$45,000 (CDC, 2011).
A national study of physicians’ intentions regarding the impact of HPV vaccine on cervical
cancer screening further indicates a reduced number of future Pap screens for women who have
had the HPV vaccine (Wong, Berkowitz, Saraiya, Wideroff, & Bernard, 2010). Internal
medicine physicians who responded to the survey agreed that vaccination would affect Pap
screening frequency by reducing the number of Pap screens needed over the lifetime of the
woman.
According to the annual report of cancer statistics, cervical cancer caused by the HPV virus
occurs most often in women aged 30 years and older (Jemal, 2009). In 2009, 11,270 women in
the United States were diagnosed with cervical cancer and 4,070 died from the disease (Jemal et
al., 2009). Healthy People 2010 created a focus on cervical cancer with Cancer Goal 3-4,
“Reduce the death rate from cancer of the uterine cervix to a target of 2.0 deaths per 100,000
4

females” (USDHHS, 2000). The rate of cervical cancer in the United States is 2.5 per 100,000
and the rate for Georgia is 2.7 per 100,000 (State Cancer Profiles, 2010). In 2006, the U.S. rate
was reported to be 2.5. Counties in Georgia with the highest mortality for cervical cancer
include Chatham, Fulton, Richmond, Gwinnett, and Cobb Counties (NCI, 2010). The National
Cancer Institute’s State Cancer Profile reported that Georgia had an estimated 364 new cases of
cervical cancer in 2006, resulting in 122 deaths from the disease (State Cancer Profiles, 2010).
However, despite having this vaccine available, only 38% of female teens in Georgia have been
vaccinated with at least one of the three doses that are necessary for HPV immunity (MMWR,
2010).
Health disparities among certain groups with higher rates of cervical cancer are noted.
Smith, Christopher and McCormick (2004) and suggest African Americans are currently 1.5
times more likely to experience an incidence of cervical cancer and two times more likely to
experience mortality than Caucasian women. Incidence rates for Hispanic and some Asian
subpopulations are also reported to be higher than Caucasian rates. Moreover, women of
Mexican descent typically receive the least preventative care services within Latina populations
(Scarinci et al., 2010). Data also suggest immigrants from Southeast Asia have the lowest levels
of Pap screens of all racial/ethnic populations in the United States (Jackson et al., 2000). Finally,
southern states, including Georgia, have a higher incidence of cervical cancer (Markowitz et al.,
2007).
While the economic impact of cervical cancer can have ill effects upon the local economy, a
more insidious economic impact is the cost of testing for cervical cancer by obtaining numerous
Pap screenings throughout the life span. The National Health Interview Survey notes that fifty
million tests for cervical cancer through Pap screens are performed annually in the United States
5

(Hiatt, Klabunde, Breen, Swan, & Ballard-Barbash, 2002). Women who follow the American
College of Gynecology guidelines will obtain multiple Pap screens during their lifetime (ACOG
Practice Bulletin, 2006). Having immunity against four of the HPV subtypes will not entirely
protect against all cervical cancers, but this protective factor may decrease the number and need
for many Pap screens during a women’s lifetime.
The FDA-approved quadrivalent HPV vaccine Gardasil® targets the HPV strains
responsible for approximately 70% of cervical cancers and 90% of genital warts making it a very
effective vaccine if given at the proper stage (Bratten & Laufer, 2008, MMWR, 2010). Yet,
despite the availability of this vaccine, it is estimated that 44.3% of eligible girls nationally and
38% in Georgia have been vaccinated with at least one of the three doses required for HPV
immunity (MMWR, 2010). There is a clear need for a better understanding of the benefits of
this vaccine.
Purpose of the Study
The purpose of this study was to examine the prevalence of Georgia physician intention and
administration of the HPV vaccine to 11-12 year-old girls, as well as the intention to recommend
the HPV vaccine to 11-12 year old boys. The study examined the attitudes and beliefs of
Georgia physicians toward administering the HPV vaccine and assessed perceived knowledge,
barriers, practices, and adherence to ACIP guidelines and recommendations regarding HPV
vaccination. A survey was administered to a random sample of 264 Georgia physicians yielding
a response rate of 82.6% (n= 218). Respondents to the survey were asked to describe their
intention and prevalence of administering the HPV vaccine to their female and male patient
population. Respondents were then asked about their knowledge of the HPV vaccine and if they
administered the vaccine according to ACIP guidelines by offering it to females at 11-12 years of
6

age. They were also asked if they recommended it according to ACIP guidelines of “permissive
use” to 11-12 year old males. Respondents were asked to respond to barriers they perceive to be
associated with this vaccine. A distinction between urban and rural was examined to determine
if there were differences. The Health Belief Model (Becker, 1974, Champion & Skinner, 2008;
Glanz, Rimer, & Viswanath, 2008) was use to inform this study of Georgia physicians.
Significance of the Study
At present, less than half the eligible girls in Georgia receive the HPV vaccine (MMWR,
2010). The body of knowledge obtained through this study, indicating how and to whom
Georgia physicians are administering the vaccine, will be beneficial in planning future
immunization actions and interventions. The current study, as designed, provided the first
comprehensive examination of HPV vaccination of physician practices in Georgia. By
addressing issues related to physician endorsement and recommendation of this vaccine, the
study will serve as an important and necessary step toward realizing the public health benefits of
HPV vaccination. This study will contribute information to the body of knowledge of HPV
vaccination in general and in particular, for the state of Georgia.
The study examined Georgia physician recommendations and prevalence of immunization
of the HPV vaccine to 11-12 year-old girls and intention to recommend the HPV vaccine to 1112 year old boys. The study examined the attitudes and beliefs of Georgia physicians toward
administering the HPV vaccine and assessed perceived knowledge, barriers, practices, and
adherence to ACIP guidelines and recommendations regarding HPV vaccination.
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Literature Review
Human Papillomavirus
According to the CDC (2010) there are more than 40 HPV types that can infect the genital
areas of males and females although subtypes 6, 11, 16 and 18 are the most prevalent. HPV is
passed on through genital contact, most often during vaginal and anal sex. HPV can be passed
on even when the infected partner has no signs or symptoms. A person can have HPV even if
years have passed since he or she had sexual contact with an infected person. Most infected
persons do not realize they are infected or that they are passing the virus to a sex partner. It is
also possible to be infected with more than one type of HPV.
HPV can cause normal cells to turn abnormal. The infected person cannot see or feel these
cell changes. In most cases, the body fights off HPV naturally and in 90% of cases, the body’s
immune system clears HPV naturally within two years (CDC, 2010). But in cases when the
body does not fight off HPV, it can cause visible changes in the form of genital warts or cancer.
Warts can appear within weeks or months after getting HPV. Cancer often takes years to
develop after getting HPV.
Genital warts usually appear as a small bump or groups of bumps in the genital area. They
can be small or large, raised or flat, or shaped like a cauliflower. If left untreated, genital warts
may resolve, remain unchanged, or increase in size or number. They will not turn into cancer.
Cervical cancer usually does not cause symptoms until it is quite advanced and difficult to treat
(Rock & Jones, 2008).
Cervical Cancer
Cervical cancer is a malignant and excessive growth of abnormal tissue of the cervical area
that left untreated may be fatal (Young, O’Dowd, & Stewart, 2010). In 2009, 11,270 women in
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the United States were diagnosed with cervical cancer and 4,070 died from the disease (Jemal et
al., 2009). The HPV infection is a necessary factor in the development of nearly 70% of all
cases of cervical cancer (Young et al., 2010). The two subtypes of HPV are types 16 and 18, and
these subtypes are the cause of over 70% of cervical cancer cases and are included in the HPV
vaccine (CDC, 2008; Markowitz et al., 2007).
TeLinde’s operative gynecology (2008) notes presentation of cervical cancer may be absent
until the cancer is in an advanced stage making it difficult for women to seek early treatment.
Cervical cancer is comprised of five stages to determine the amount of cancer in the body. In the
initial Stage, or Stage 0, abnormal cells are found in the deepest lining of the cervix. Stage 0 is called
carcinoma in situ and is found in the cervix. Stage 0 is followed by Stage I which includes

growth of the cancer. The five year survival rate for Stage I range from 80-99%. Common
treatments include surgery, chemotherapy and radiation (NCI, 2010).
In Stage II, cancer has spread beyond the cervix but not into the pelvic wall or to the lower third
of the vagina. Five-year survival is 65-69%. Common treatments for Stage II cervical cancer include
surgery, radiation and chemotherapy (NCI, 2010).
In Stage III, cancer has spread to the lower third of the vagina and may have spread to the pelvic
wall. With advanced cervical cancer, the woman has symptoms of weight loss, a vague feeling

of fatigue, pelvic pain, back pain, leg pain, a single swollen leg, heavy bleeding from the vagina,
possible leaking of urine or feces from the vagina, or bone fractures (Rock & Jones III, 2007).
Five-year survival at this state is 40-43 %. Common treatments include chemotherapy and radiation
(NCI, 2010).
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In Stage IV, the cancer has left the pelvis and spread to the bladder, rectum, or other parts of the
body such as the abdomen, liver, intestinal tract, or lungs. The five-year survival rate for this stage
of cancer is 15-20 %. Types of treatment include chemotherapy and radiation (NCI, 2010).

Each year the American Cancer Society (ACS) publishes a summary of recommendations
for early cancer detection and a report on data and trends in cancer screening rates. The ACS
reviews current guidelines by the US Preventive Services Task Force and from the American
College of Obstetricians and Gynecologists (ACOG). The ACS screening guidelines for cervical
cancer recommend different surveillance strategies and options based on the woman’s age,
screening history, other risk factors, and the choice of screening tests (Smith, Cokkinides,
Brooks, Saslow, & Brawley, 2010). The ACS guidelines for cervical cancer screening were
updated in 2009 to include best practices since the changes made in the 2002 update. The 2009
ACS guidelines recommend screening for cervical cancers begin at age 21 years. Until age 30,
and according to the guidelines, women at average risk receive biannual Pap screening using
liquid-based cytology. After age 30 years, women with normal or negative Pap screens may
choose either to undergo screening every three years using either conventional or liquid-based
cytology, or undergo screening every three years with the combination of HPV-DNA testing and
conventional or liquid-based cytology (Smith et al., 2010; Waxman, 2009).
The current guidelines recommend women who have an intact cervix and who are in good
health continue screening until age 70 years, and afterward may choose to stop screening if they
have had no abnormal or positive cytology tests within the 10-year period prior to age 70 years,
and if there is documentation that the three most recent Pap screens were technically satisfactory
and interpreted as normal. However, screening after age 70 years is recommended for women in
good health who have not been previously screened, women for whom information about
10

previous screening is unavailable, and women for whom there is a low likelihood of past
screening (Smith et al., 2010; Waxman, 2009).
The US Public Health Service and Infectious Disease Society of America also have
recommendations for cervical cancer screening. The US Public Health Service and Infectious
Disease Society of America recommend women with a history of cervical cancer or in utero
exposure to diethylstilbestrol (DES) follow the same screening guidelines as average-risk women
before age 30 years, and continue with that protocol after age 30 years. Women who are
immunocompromised by organ transplantation, chemotherapy, chronic corticosteroid treatment,
or who are human immunodeficiency virus (HIV) positive should be tested twice during the first
year after diagnosis, and annually thereafter. There is no specific age to stop screening for
women with a history of cervical cancer, with in utero exposure to DES, and who are
immunocompromised. Women in these risk groups should continue cervical cancer screening
for as long as they are in reasonably good health and would benefit from early detection and
treatment (Smith et al., 2010).
In November 2009, ACOG presented their updated guidelines for cervical cancer screening
that recommended screening beginning at an older age and longer screening intervals for women
in all age groups. According to ACOG’s Cervical Cytology Screening (2009) the significant
changes in the new guidelines include a set age to begin screening regardless of age of onset of
vaginal intercourse, a lengthening of the screening interval by one year, and the establishment of
an age to stop screening if there is a 10-year history of normal screening tests.
History of Vaccines
All humans have some amount of natural immunity to disease and infection. Immunization
is the process of artificially creating immunity by deliberately infecting a person so the body
11

learns to protect itself (Waterson, 1978). A vaccine causes the body’s immune system to
produce antibodies to fight a modified form of the virus that is not harmful. Then, if the person
encounters the real and dangerous virus, the body is able to protect itself (Waterson, 1978).
The concept of immunization, or how to artificially induce the body to resist infection,
received widespread recognition in 1796, when British physician Edward Jenner inoculated a
young boy in England and successfully prevented him from getting smallpox. Jenner used a
lancet to scratch infected material from a woman with cowpox which is very similar to smallpox,
under the boy’s skin (Riedel, 2005).
Vaccines work in the same manner and deliver minute amounts of substances that provoke
antibody responses called antigens. Antigens multiply more slowly and for a shorter period of
time than their disease-producing counterparts. As a result, the body recognizes just enough
antigens to develop protective antibodies (CDC, 2009). Today there are 15 different vaccines
children may receive prior to their 21st birthday (Immunization Action Coalition, 2010)
HPV Vaccine
The quadrivalent human papillomavirus vaccine Gardasil® developed by Merck
Pharmaceuticals for females prevents infection from serotypes 6, 11, 16, and 18, which are the
four most common serotypes of human papillomavirus associated with the development
of cervical cancer, genital warts, and some less common cancers (CDC, 2008). The HPV
vaccine Gardasil® protects against two of the HPV types 16 and 18 that cause approximately
70% of all cervical cancer. In addition, the quadrivalent HPV vaccine also protects against two
additional HPV types 6 and 11 that cause most genital warts (CDC, 2008). It is the only vaccine
which prevents against these four HPV types (CDC, 2008).
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The safety and efficacy of the vaccine continues to be studied and documented. In females,
a four year evaluation of the prophylactic efficacy of the HPV vaccine in preventing low grade
cervical, vulvar, and vaginal intraepithelial neoplasias and anogenital warts, indicated sustained
protection against low grade lesions attributable to vaccine HPV subtypes 6, 11, 16, and 18 and a
substantial reduction in the burden of these diseases through 42 months of follow-up (Dillner et
al., 2011). In addition, researchers from the University of Massachusetts conducted an extended
literature search on the safety and efficacy of the HPV quadrivalent vaccine. These researchers
reviewed multiple bibliographic databases and concluded the vaccine was effective in the
management of HPV by preventing vaccine subtype-related persistent infection and
precancerous lesions.
Research by Giuliano et al. (2011) on 4,065 healthy males 16-26 years of age from 18
countries in a double-blind trail examined safety of the HPV vaccine against active HPV types 6,
11, 16, and 18 and efficacy in preventing the development of external genital lesions and
anogenital HPV infection in boys and men. The primary efficacy objective was to show that the
quadrivalent HPV vaccine reduced the incidence of external genital lesions related to HPV-6, 11,
16, or 18. The conclusion of this study was quadrivalent HPV vaccine prevents infection with
HPV-6, 11, 16, and 18 and the development of related external genital lesions in males 16 to 26
years of age.
The vaccine was also regarded as generally safe and well-tolerated, based on an assessment
of reported adverse events submitted through governmental databases and analyzed by
independent researchers (Pomfret, Gagnon, Jr., & Gilchrist, 2011).
On October 16, 2009, the FDA licensed bivalent HPV Cervarix® manufactured by
GlaxoSmithKline pharmaceuticals for use in females aged 10 through 25 years. Cervarix® is the
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second HPV vaccine licensed for use in females in the United States and contains two HPV types
rather than four types like the Gardasil® vaccine. It is not licensed for males. It protects against
HPV types 16 and 18, the causes of most cervical cancers (MMWR, 2010). Cervarix will not be
included in this research because it is not covered by the VFC program.
Public health officials in the United States recommend vaccination of young women against
HPV noting that as many as 80% of American women will have contracted at least one strain of
HPV by age fifty (Dunne et al., 2007). In 2000, genital HPV cost the nation $2.9 billion in direct
medical costs (Chesson, Blandford, Gift, Tao, & Irwin, 2004). Since neither vaccine covers all
high-risk types of HPV, experts continue to recommend regular Pap smear screening even after
vaccination (NCI, 2010; Markowitz et al., 2007).
The ACIP recommends the HPV vaccine be administered to females by intramuscular
injection in the upper arm. The recommended schedule is a three-dose series with the second
dose administered two months after the first dose. The third and last dose is given six months
after the first dose. The recommended age for vaccination of females is 11-12 years. The
vaccine can be administered to girls as young as 9 years old. Catch-up vaccination is
recommended for females aged 13-26 years who have not been previously vaccinated
(Immunization Action Coalition, 2010).
A recommendation from the American Academy of Pediatrics was made in 2007 (AAP,
2007) recommending the vaccine to the pediatrician’s female patients. The American Academy
of Family Physicians followed and recommended the vaccine to their female patients in 2007
(Goeser, 2007).
Until this time, the HPV vaccine was licensed only for young females. It was not until
October 16, 2009, that the FDA licensed quadrivalent human papillomavirus vaccine, Gardasil®
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as the only HPV vaccine for use in males 9 to 26 years for prevention of genital warts caused by
human papillomavirus types 6 and 11. (MMWR, May 28, 2010). Efficacy and safety of the
vaccine for males in preventing the development of external genital lesions and anogenital HPV
infection was performed on male’s age 16 to 26 years (Giuliano et al., 2011). Their research
indicated the quadrivalent HPV vaccine reduced the incidence of external genital lesions related
to HPV subtypes 6, 11, 16, or 18, and reduced the development of related external genital lesions
in males 16 to 26 years of age.
After FDA approval, and on October 21, 2009, the ACIP provided guidance stating the HPV
vaccine may be given to males aged 9 through 26 years to reduce their likelihood of acquiring
genital warts. The ACIP did not recommend the HPV vaccine for routine use among males.
Instead, the committee voted to support the "permissive use" of the HPV vaccine among males,
leaving decisions on whether to immunize males ages 9-26 years who request the vaccine to the
discretion of their health care professional (MMWR, May 28, 2010). In December 2010, The
FDA also approved the HPV vaccine Gardasil® for the prevention of anal cancer and associated
precancerous lesions due HPV sub types 6, 11, 16, and 18 in both males and females age 9
through 26 years (FDA, 2010).
The ACIP recommends the HPV vaccine be administered to males by intramuscular
injection in the upper arm. The recommended schedule is a three-dose series with the second
dose administered two months after the first dose. The third and last dose is given six months
after the first dose. The recommended age for vaccination of males is 11-12 years. The ACIP
allows the vaccine to be administered to those as young as age 9 years and through age 26
(MMWR, May 28, 2010).
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Barriers Related to HPV Vaccine Administration
Research shows many important links between barriers and intention to vaccinate and how it
affects vaccination rates. The causal relationship between HPV and cervical cancer is a
relatively recent discovery with clinical trials for the vaccine beginning in the 1990’s (Markowitz
et al., 2007). Since its discovery in 1956, HPV has been intensely studied. Physician and
scientist Harald zur Hausen first postulated in 1983 that HPV caused cancer in women (zur
Hausen, 1996). Zur Hausen (1996) was able to unveil HPV’s novel properties and proved that
two HPV subtypes (16 and 18) could cause as much as 70% of cervical cancer cases. In 2008,
zur Hausen received the Nobel Prize for his work on HPV (Nobel Prize, 2008).
As detailed in a systematic review by Allen et al. (2010), most research on this topic was
conducted prior to vaccine licensure in 2006. In their review, it was noted that at least two-thirds
of existing U.S. studies and 36% of non-U.S. studies were conducted prior to HPV vaccine
licensure. With this consideration, barriers to HPV vaccination will be summarized below.
Informational Barriers
Lack of information and education is identified by many researchers as a barrier to HPV
vaccination. Information and education barriers for young women, parents of adolescent girls,
and physicians are well documented (Chan, Cheung, Lo, & Chung, 2007; Mays, Sturm & Zimet,
2004; Olshen, Woods, Austin, Luskin, & Bauchner, 2005; Woodhall, 2007). Multiple studies
suggest parents and young women often are not aware of the risks of contracting HPV or its
direct association to cervical cancer (Chan, Cheung, Lo, & Chung, 2007; Dempsey & Davis,
2006; Gerend, Lee, & Shepherd, 2007; Hoover, Carfioli, & Moench, 2000). Lack of information
may also impede physicians from recommending the vaccine if they are not aware of the benefits
of vaccination, or how to educate about the benefits of the vaccine. In a New Mexico study
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involving 37 primary care providers, researchers revealed barriers to counseling parents on HPV
vaccination included limited knowledge of HPV and low levels of knowledge by adolescents
(Sussman et al., 2007). Throughout the literature, researchers recommended continued
educational outreach and interventions for parents, women, and physician healthcare providers.
Safety and Efficacy Barriers
There are concerns by physicians, parents, and young women, about vaccine safety and
efficacy. According to published research, there have been more than 26 million doses of the
HPV vaccine distributed in the United States with 12,424 reports of adverse reactions. Most
adverse events rates were no greater than background rates compared with other vaccines, but
there was disproportional reporting of syncope and venous thromboembolic events with the HPV
vaccine (Slade et al., 2009).
In a study of 513 pediatricians using a traditional mail survey, pediatricians reported
concerns about the safety of the vaccine and uncertainty regarding the efficacy of the vaccine in
terms of lifetime protection for individuals (Kahn et al., 2005). In an editorial in the Journal of
American Medicine, Gostin and DeAngelis (2007) caution physicians to consider the lack of
adequate efficacy trials for girls aged 9 to 15 and recommend more trials be completed before
mandating the vaccine for school enrollment. Other concerns by parents and young women
focus on potential harmful side effects from the vaccine and the general safety of the vaccine
(Gerend et al., 2007; Marshall, Ryan, Roberton, & Baghurst, 2007; Woodhall et al., 2007).
Cultural Barriers
Cultural barriers in the literature focus on race, ethnicity, socioeconomic status, education
level and health insurance status (Sussman et al., 2007). According to the American Cancer
Society (2009), Latinas have higher cervical cancer age-adjusted incidence and mortality rates,
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and present with more advanced disease compared to non-Latino whites. Research to determine
HPV awareness among Latina immigrants and Anglo women in the southern United States
suggested Mexican and Honduran women were less likely to be aware of HPV and the HPV
vaccine, and more likely to be uninsured and without a regular health care provider than Anglo
women (Luque et al., 2010).
In a study of Hispanic women in New Mexico that included a series of focus groups,
participants indicated physicians should consider relevant cultural issues (Vanslyke et al., 2008).
The researchers noted Hispanic men may put their sexual partners at heightened risk for HPV
due to cultural tolerance of refusing to wear condoms and engaging in sexual activities outside of
a committed relationship. In another qualitative research study with Hispanics conducted in
south Georgia for the purpose of developing cervical cancer education curriculum for lay health
worker outreach, study participants reported cultural barriers for cervical cancer screening,
primarily regarding feelings of embarrassment, and not having permission from their husbands to
go to the clinic (Luque, et al., In Press).
In a qualitative study, Tissot et al. (2007) found pediatricians had concerns about parents’
anti-vaccination beliefs, particularly parents who have strong religious beliefs or who believe in
holistic approaches to healing. This study noted African Americans were less trusting of
physicians and vaccines. The study also reviewed socioeconomic factors and suggested lower
education and income may decrease parental ability for those who seek vaccination. However,
the study also suggested those with higher income and education may not consider their children
vulnerable and so would be less willing to seek vaccination. Issues of higher income and lower
education status were found to be barriers to intentions in other studies as well, regardless of race
(Hopenhayn et al., 2007; Woodhall et al., 2007).
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Psychological Barriers
Psychological barriers are barriers associated with personal concerns with HPV vaccination.
These barriers are placed in two broad categories. The first category is concerns by the
vaccinating physicians regarding attitudes of parents toward the vaccine that prevents an STD,
and obtaining parental consent (Dempsey & Davis, 2006; Kahn et al., 2005; Sussman et al.,
2007). The second category is by parents of young women. The parental concern is that HPV
vaccination encourages promiscuity. Another concern in the parental category is the perception
of there being little personal risk of HPV infection for their children (Brewer & Fazekas, 2007;
Marshall et al 2007; Woodhall, et al., 2007).
Financial Barriers
The HPV vaccine, Gardasil®, is the most expensive vaccine recommended for children and
adolescent with a reimbursement cost of $360, compared with other recommended vaccines that
are less than $50.00 (Gudeman, 2007). Women with health insurance report this does not
necessarily make the HPV vaccine affordable if their health insurance plan does not cover the
cost (Hopenhayn et al., 2007). As a result, some physicians report keeping their vaccine
inventory low and will only offer it to those patients whose coverage will provide reimbursement
(Daley, 2006; Gudeman, 2007).
This upfront or initial cost of purchasing HPV vaccine places a significant financial burden
on physicians who must purchase it for their patients with insurance or otherwise do not qualify
for the federal and state Vaccine for Children (VFC) immunization program. The VFC program
provides free vaccines to qualifying children based upon income (Dempsey & Davis, 2006).
Indeed, Gudeman (2007) notes that while the VFC program offers vaccine at no cost to
underinsured adolescents, there is limited access to VFC discounts if the physician is not part of
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the VFC program. There is further limited access if there is a lack of presence of Federally
Qualified Health Centers or a Rural Health Clinics in the geographic area.
Religious Barriers
Cultural considerations which include religious beliefs and implication toward vaccination
have been studied by many (Askelson, 2010; Borrayo & Jenkins, 2003; Chan et al., 2007; Charo,
2007; Daley et al., 2006; Katz et al., 2009; Hoover et al., 2000; Tissot et al., 2007). Their
research suggests strong religious beliefs lead to a delay of vaccine administration until an older
age or omitting the vaccine altogether. According to qualitative review of the relevant literature
by Zimet (2005), religious conservatives voiced concern that allowing their daughters to receive
the vaccine undermines abstinence teaching. This argument is similar to that used against
school-based sex education programs and condom distribution (Zimet, Shew, & Kahn, 2008).
Compliance Barriers
The HPV vaccine is the only vaccine offered to older children and requiring a three-dose
series (McIntosh, Sturpe, & Khanna, 2008). This may present a compliance challenge for some
female patients. Patients particularly vulnerable are those populations with limited access to
transportation or who must take off work repeatedly to complete the three dose series (Herzog,
Huh, Downs, Smith, & Monk, 2008). In addition, this older age group does not have as much
routine contact with physicians as when they were younger and receiving medical visits for
growth and development monitoring. In Georgia, and according to the Medicaid periodicity
schedule of visits, physicians are reimbursed for one annual health check visit during
adolescence. Other visits to the physician must be a problem focus visit to qualify for
reimbursement ("Health check services", 2007; McIntosh et al., 2008). Most insurance
companies follow this guideline and limit the number of routine office visits. Requiring three
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visits for the vaccine series can place an added burden on both patient and physician in terms of
scheduling, vaccine availability, and the above noted limits placed on the number of visits
covered for adolescent well-visits by insurance and other third party reimbursement programs.
Reimbursement and getting to the physician’s office are not the only compliance barriers.
Other researchers found completing the vaccine three dose series to be a barrier even when the
vaccine was provided within a school setting, as students missed their scheduled appointments
(Brabin et al., 2008). This same study also found uptake was significantly lower in schools with
a higher proportion of ethnic minority girls or if there was a higher proportion of girls entitled to
free school meals (Brabin et al., 2008).
Supports Related to HPV Vaccination
Similar to barriers, there are supports noted in the literature that encourage HPV vaccination.
Financial supports and health behavior were reported most often as supports (Kahn et al., 2008;
Spereber, Brewer, & Smith, 2008). Other common supports included in the literature comprise
physician recommendations and organizational supports (Kahn et al., 2009; McCave, 2010).
Supports to HPV vaccination will be discussed in greater detail in the following sections.
Financial Supports
The financial burden of the HPV vaccine has been a concern for patients of lower socioeconomic status and providing financial support to physicians and patients is important.
Physicians, women, and parents indicate that having the vaccine covered fully by insurance is
necessary, as is making it affordable for those without insurance (Kahn, et al., 2005; Hoover et
al., 2000).
The most significant financial support is the inclusion of the HPV vaccine in the VFC) list
of federally covered vaccines. The CDC’s Section 317 Grants Program is the main source of
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funding for state immunization programs. States use these federal funds to pay for underinsured
patients to cover their vaccine costs under Section 317 of the Vaccination Assistance Act of 1962
(Rein, Honeycutt, Rojas-Smith, & Hersey, 2006; Institute of Medicine, 2003).
The VFC program is a federal entitlement program established in 1994. Research published
in the Journal of American Medical Association, notes that VFC funds account for
approximately 43% of vaccine expenditures (Lee et al., 2007). The VFC program provides free
immunization services to uninsured and underinsured children up to age 19 to participating
physicians, Federally Qualified Health Centers and Rural Health Clinics (Institute of Medicine,
2004). Once the ACIP adds a vaccine to the recommended childhood/adolescent immunization
schedule and votes to include the vaccine for use under the VFC program, the vaccine must be
subsidized under VFC for qualified children (Orenstein, Rodewald, Hinman, 2004). Parents who
support a mandatory HPV vaccination are aware of the VFC program and how it could improve
coverage for those with limited financial resources (Ferris, Horn, & Waller, 2010).
The Georgia VFC program, which began October 1994, is coordinated by the Georgia
Immunization Program within the Division of Public Health through the Department of
Community Health (Georgia Department of Community Health, 2010). Georgia’s VFC Program
provides free vaccines to private and public providers including physicians, for children up to 18
years old who are Medicaid-eligible, American Indian/Alaska Native, uninsured, and
underinsured (Immunization in Georgia, 2009). As of December 2004, 3,062 private physicians
at 1,025 locations participate in the VFC program in Georgia (Immunization in Georgia, 2009).
A study of adosescent girls enrolled in the Florida Medicaid VFC Program, which offers the
HPV vaccine, indicated girls in this program were more likely to have initiated the HPV vaccine
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series if the financial barrier of cost was removed (Staras, Vadparampil, Haderxhanai, &
Shenkman, 2010).
Organizational Supports
Organizational supports provided by primary care settings such as clinics and private
practices have been discussed in the literature (Bhatla et al., 2010; Chao, Velicer, Slezak, &
Jacobsen, 2010; Humiston et al., 2009). Creating physician office supports, such as decreasing
time constraints and providing information to parents, was found to be effective (Chan et al.,
2007).
In a qualitative study of 31 pediatricians by Tissot et al. (2007), potential supports for
improving HPV vaccination were considered. The findings for supports included a number of
strategies that pediatricians believed were critical for effective future implementation of HPV
vaccination. These included: 1) maximizing ease of vaccine administration; 2) implementing
office-based procedures and policies to optimize vaccine uptake; 3) ensuring broad access to
vaccines; 4) ensuring endorsement of vaccination by influential organizations; and 5) addressing
the educational needs of providers, parents, and patients (Tissot et al., 2007, p. 124). Supports
included providing lectures and written materials, such as information sheets and professional
organization policy materials. Other supports included hosting local expert guest speakers,
directing patients to informational web sites and providing data on HPV prevalence and
susceptibility, HPV-related diseases, and health impact and devising strategies for talking with
parents and youth in a culturally sensitive way were also incorporated (Tissot et al., 2007).
In Georgia, a statewide web portal internet system is able to assist providers who administer
vaccine by allowing them to access vaccine information on any individual who has received a
vaccine in Georgia. The Georgia Immunization Registry law was passed in 1996 and the
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Georgia Registry of Immunization Transactions and Services (GRITS) were introduced
statewide to include vaccination history on childhood vaccines in May 2003. It was expanded by
House Bill 1526 in 2004 to require reporting by any person who administers a vaccine or
vaccines licensed for use by the FDA, to a person from birth to death, be recorded in the GRITS
statewide vaccine registry (Georgia General Assembly, 2004).
Among other benefits, the internet based GRITS immunization registry allows enrolled
physicians and other providers, both public and private, to input and access any individual’s
complete immunization record. This access decreases over and under immunization, and
provides a current picture of the immunization status of all Georgians including that of the HPV
vaccine. The benefits are beginning to be realized as the GRITS registry is used in populationbased research for children behind schedule in receiving immunizations and provides a reminder
to those who require the second and third dose of a series immunization such as the HPV vaccine
(DHR - Immunization in Georgia, 2006).
Physician Recommendation as a Support
HPV vaccine acceptability by parents and young women is greater when they perceive that
their health provider recommends the vaccine (Gerend et al., 2007; Tedeschi et al., 2006).
Indeed Sussman et al. (2007) listed four factors important in the counseling process: 1) the
importance of rapport building with adolescents; 2) the assumption that adolescents will engage
in high-risk behaviors; 3) the difficulty and complexity of counseling about the HPV vaccine;
and 4) the attitudes of primary care providers, nurse practitioners, and community acceptance of
the HPV vaccine. In a national survey of pediatricians by Daley et al. (2006), respondents were
more likely to recommend HPV vaccination to older compared to younger adolescents. They
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further noted respondents were more likely to recommend vaccine to female versus male patients
(Daley et al., 2006, p. 2284).
McCave (2010) noted supports necessary for improving HPV vaccination rates include a
personal belief in the positive impact of the HPV vaccine. This was followed by providers
feeling comfortable talking with parents about the sexual nature of diseases prevented by the
vaccine, and the importance of adhering to the CDC's recommendations on HPV vaccination.
McCave further noted age of the patient likely influenced the providers' HPV vaccination
behaviors, particularly if parents have concerns about vaccinating their pre-adolescent child. She
concluded her finding by stating providers can best serve their patients when they are aware of
the potential barriers and supports that may influence their HPV vaccination behaviors.
In a study of physicians currently administering the vaccine to females, findings suggest
physicians supported the concept of vaccinating males for the benefits it imparts on both sexes.
The physicians in the study agreed a gender-neutral HPV vaccination recommendation would be
appropriate with regard to public health but were less sure that such a recommendation would
change patient or parental attitudes toward HPV vaccination or improve current HPV vaccination
efforts (Weiss, Zimet, Rosenthal, Brenneman, & Klein, 2010).
State Law and the HPV Vaccine Mandate for School Admission
In a report by the Institute of Medicine, state immunization programs, including Georgia,
have seen an increase in the number of new and expensive vaccines (Institute of Medicine,
2003). The newer vaccines improve the health of the child immunized and prevent many
diseases that were once common to childhood. However, according to the latest price lists
published by the CDC, the total cost dose to fully vaccinate a child in Georgia at a physician’s
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office has risen from $155.00 in 1995 to over $1,200.00 in 2010 (CDC Pediatric/VFC Pricelist,
2010).
Historically, the preservation of the public’s health has been the responsibility of state and
local governments, and the authority to enact laws relevant to the protection of the public health
derives from the state’s general police powers (Gostin, 2008). All states in the United States
have mandated various types of vaccines for school-aged children. The most persuasive case for
a mandate is when the vaccine prevents a serious infectious disease spread by casual contact in
the age group for which it is mandated. Examples of mandated vaccines in this category are
those that protect against polio, measles, mumps, rubella, diphtheria, and pertussis. Exemptions
to vaccinations are available in cases of religious convictions. However, widely used vaccine
exemptions result in a lowering of what epidemiologists refer to as "herd immunity," and result
in an increase in disease (CDC, 2006).
In February 2007, Texas became the first state to mandate the HPV vaccine for girls
entering sixth grade. Texas legislators were not supportive and by May 2007 passed a bill
reversing the governor's order for the mandate and instead mandated that no HPV vaccine could
be ordered for schoolchildren over the next four years (Javitt, Berkowitz, & Gostin, 2008).
During this same time, a cross-sectional, web-based survey of Texas physicians was conducted
to determine three outcome variables pertaining to HPV vaccination. These were: HPV vaccine
recommendations to 11-to-12-year-old girls, probability of recommending the vaccine to 11-to12-year-old boys, and agreement with the mandated vaccination of 11-to-12-year-old girls. Of
the 1,122 respondents to the survey, over half of physician respondents did not follow current
recommendations for universal HPV vaccination of 11-to-12-year-old girls (Kahn et al., 2009).
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In Georgia, lawmakers determined the HPV vaccine does not meet the high threshold
necessary for school entry. Namely, HPV is spread by sexual or very close contact and therefore
is not an epidemic infectious disease among school-aged children requiring it to be a mandated
vaccine (National Conference of State Legislatures, 2010). Therefore the state of Georgia does
not mandate the HPV vaccine as a required vaccine for school admission (Georgia Department
of Education, 2010).
Georgia Public Health Districts
Georgia Department of Community Health, Division of Public Health is the lead division
entrusted by the people of the State of Georgia with the ultimate responsibility for the health of
communities and the entire population. At the state level, the Division of Public Health is
divided into numerous branches, sections, programs and offices (Georgia Department of
Community Health, 2010). At the local level, the Division of Public Health functions through 18
health districts which contain the 159 county health departments (Appendix A).
The Immunization Section of the Division of Public Health works collaboratively with
public and private providers, advocacy groups, and other stakeholders, to increase immunization
rates for all Georgians and decrease the incidence of vaccine-preventable diseases. Each of the
159 counties has some public health presence and the ability to administer the HPV vaccine.
According to Dr. Anil T. Mangla, Director of the Immunization Section of the Division of
Public Health, a population-based study conducted in Georgia in 2004 showed most childhood
immunizations (70%) were administered in the private sector at the physician office, while 14%
were administered by county health departments. The sources for 16% were unknown though
some were expected to be Federally Qualified Health Centers located in low income areas (A. T.
Mangla, personal communication, October, 2010). A Georgia immunization study conducted in
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2007 revealed that most childhood immunizations (81%) were administered in the private sector
at the physician office, while county health departments immunized 9.8%, and the sources for
9% were unknown, indicating more children are receiving vaccines at physician offices (Georgia
Department of Community Health, 2010). The Georgia Division of Public Health does not
record information on physician HPV vaccination administration rates. However, according to a
CDC report, Georgia physicians vaccinate one in three females eligible for HPV (MMWR,
2009). As the Mission and Vision of the Immunization Section of the Division of Public Health
is to “… work to increase immunization rates for all Georgians and decrease the incidence of
vaccine-preventable diseases,” it is important that the Immunization Section of the Division of
Public Health have information about the attitudes and beliefs of Georgia physicians toward
administering the HPV vaccine and assess perceived knowledge, barriers, practices, and
adherence to ACIP guidelines and recommendations regarding HPV vaccination.
Urban and Rural Classification of Georgia Counties
This research sought to determine differences between urban and rural physicians’
administration and recommendation of HPV vaccine. According to a health care workforce
report commissioned by the U.S. Department of Health and Human Services, it was noted
Georgia’s rural population lacked adequate geographical access to basic health care services
(Bureau of Health Professions, 2011). According to their report, the percent of Georgia’s
population residing in primary care federally-designated health professional shortage areas
(HPSAs) exceeds the national proportion. Rural areas continue to have difficulty recruiting
primary care physicians and Georgia’s community health centers in underserved areas voice
growing concerns about their difficulty recruiting and retaining physicians (Bureau of Health
Professions, 2011).
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As this present research sought to determine differences between urban and rural physicians’
administration and recommendation of HPV vaccine, the terms urban and rural had to be defined
to determine if differences emerged between vaccination rates in rural or urban defined areas.
Rural is an imprecise term that can mean different things to different researchers. For example,
what is considered rural in one state with low population density may not be considered rural in
another state with a much higher density. However, for the purposes of this proposed research,
there is a need for exact definitions of what is meant by "rural."
Government agencies considered whose definitions of what is rural or urban include: 1) the
U.S. Census Bureau; 2) the Office of Management and Budget; 3) the Economic Research
Service of the U.S. Department of Agriculture (USDA); and 4) the Georgia Office of Rural
Health.
According to the U.S. Census Bureau, specific urban entities are defined as an urbanized
area and include an urban nucleus of 50,000 or more people. Individual cities with a population
of 50,000 may or may not be contained in an urbanized area. Urbanized areas have a core with a
total land area less than two square miles and a population density of 1,000 persons per square
mile. They may contain adjoining territory with at minimum 500 persons per square mile and
encompass a population of at least 50,000 people. An urban cluster also has a core as identified
above with a total land area of less than two square miles and a population density of 1,000
persons per square mile. They may contain adjoining territory with at minimum 500 persons per
square mile and encompass a population of at least 2,500 but less than 50,000 persons (United
States Census Bureau, 2010).
A second definition of rural is offered by the Office of Management and Budget, which
defines metropolitan statistical areas - or metro areas - as central or core counties with one or
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more urbanized areas, and outlying counties that are economically tied to the core counties as
measured by work commuting (Office of Management and Budget, 2010). They include
outlying counties if 25% of workers living in the county commute to the central counties, or if
25% of the employment in the county consists of workers coming out from the central countiesthe so-called "reverse" commuting pattern. Non-metro counties are outside the boundaries of
metro areas and are further subdivided into two types.
The Office of Management and Budget use the term “Micropolitan statistical areas “or
“micro areas” to denote non urban areas. These are non-metro counties with an urban cluster of
at least 10,000 persons or more (Office of Management and Budget, 2010). The last type is the
noncore county. Researchers and others who discuss conditions in rural America often refer to
nonmetropolitan areas that include both micropolitan and noncore counties as rural areas (Office
of Management and Budget, 2010; Rural Assistance Center, 2010).
A third definition is through the offices of The Economic Research Service. This includes
the United States Department of Agriculture (USDA), the Department of Health and Human
Services, Health Resources and Service Administration's Office of Rural Health Policy along
with Rural Health Research Center, and the University of Washington which collaborated to
develop the Rural-Urban Commuting Area system. Their definition is a census tract-based
classification that utilizes the Bureau of Census urbanized area standard and place definitions in
combination with commuting information to characterize rural and urban status of census tracts
(United States Department of Agriculture Economic Research Center, 2010).
The fourth and final definition is used by the Georgia Office of Rural Health. The Georgia
Office of Rural Health defines a Georgia rural county as any county having a population of less
than 35,000 according to the U.S. Census of 2000 (Rural Assistance Center, 2010). Since this
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study involved research pertaining to possible differences between urban and rural HPV vaccine
administration of Georgia physicians by county, this study will use the Georgia Office of Rural
Health Classification for rural counties. Therefore, those counties with less than 35,000 will be
classified as rural and those with greater than or equal to 35,000 will be classified as urban.
Use of Theory
This study relied upon theory to inform the development of the research questions and
interpret the findings. Health improvements, such as providing HPV vaccination to one’s
patients, cannot be completed by simply providing the physician with information and raising his
or her awareness to the need to educate parents about HPV.
Indeed, ecological models suggest that multiple levels must be in place for change to occur.
Stokols (1996) notes successful health improvement and promotion programs must link
behavioral strategies with efforts to strengthen environmental supports within the broader
community that are conducive to well being. Using the social ecological approach, there are
alternative yet complementary perspectives. The social ecological model considers the complex
interplay between individual, relationship, community, and societal factors by allowing us to
address the four factors, or levels that put people at risk (Stokols, 1996).
The first level looks at the broad societal factors that help create a climate in which HPV
vaccination is encouraged or inhibited. These factors include social and cultural norms. Other
large societal factors include the health, economic, educational and social policies that help to
maintain economic or social inequalities between groups in society (Stokols, 1996).
The second level explores settings such as the physician workplace, and organizations in
which social relationships occur. It also seeks to persuade or dissuade providing HPV
vaccination.
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The third level encompasses relationships with peers, professional partners, and family
members. Factors include whether or not other trusted physicians are providing the vaccine, and
if valued sources of information such as professional journals and associations, encourage
vaccination.
The first level, or individual level, identifies biological and personal history factors. In this
research, factors associated with the first level include age, education, and personal feelings
toward HPV vaccination. In this level, the Precaution Adoption Process Model was explored to
determine if it would inform the research undertaken.
The Precaution Adoption Process Model was first suggested by Weinstein (1988) as a model
used to describe and explain the process by which people adopt precautions against a new risk.
For example, a risk that they have recently learned about rather than a risk they have been aware
of for some time. It is applicable in the situation where a new precaution against an "old" risk
becomes available such as the introduction of the HPV vaccine to prevent cervical cancers and
genital warts.
The Precaution Adoption Process Model specifies seven discrete stages. It defines the
stages without reference to arbitrary time periods and, between having never thought about
adopting a particular precaution and having thought about it and decided not to act. In each stage
the types of information and interventions needed to move people closer to action varies
(Weinstein, 1988). One advantage of such a stage theory is that it useful when the same
population is being surveyed over time or targeting interventions to move people through stages.
It was not used in this research as the survey was administered once and follow up surveys to the
sample were not part of this research. Next, the health belief model was explored to inform this
research.
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Health Belief Model
The central premise that a primary care provider’s perceived barriers and benefits of
providing HPV vaccine to her clients, which stem from the physician’s personal or normative
beliefs as well as perceived severity and susceptibility of diseases associated with the human
papillomavirus, and her recommendation and administration of the vaccine is the foundation for
this study.
The Health Belief Model was created to provide a framework to better understand why some
people take actions to avoid illness, whereas others do not (Becker, 1974). This model was
developed by social psychologist researchers with the U.S. Public Health Service in the early
1950s (Becker, 1974; Champion & Skinner 2008; Rosenstock, 1974). The U.S. Public Health
Service researchers were motivated to study why people sought radiographic examinations for
tuberculosis and why others did not. They created a theory that attempted to explain and predict
given health-related behavior from certain patterns of belief about the recommended health
behavior and health problems that the behavior was intended to prevent or control. The model
postulates that the following conditions both explain and predict a health-related behavior:
1. A person believes their health is at risk or their chances of getting a condition. For the
behavior of seeking screening or treatment, the person must believe that he/she can have
the disease yet not feel symptoms. This collection of beliefs is referred to as "perceived
susceptibility."
2. The person perceives the potential seriousness of the condition in terms of pain or
discomfort, time lost from work, economic difficulties, or other negative outcomes. This
belief is referred to as “perceived severity.”
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3. On assessing the circumstances, the person believes that benefits derived from the
recommended behavior (such as obtaining an immunization) outweigh the costs and
inconvenience and that they are indeed possible and within her ability to acquire. These
perceived or anticipated benefits and costs are referred to as “perceived benefits.”
4. Before taking action, the person must determine the tangible and psychological costs of
the action and barriers. Then the barriers must be reduced through reassurance,
incentives and/or assistance. This is referred to “perceived barriers.”
5. The person receives strategies to act or a precipitating force that makes the person feel
the need to take action. This is referred to “cues to action.”
6. Finally, the person must have confidence is their own ability to take action. This final
step is referred to as “self-efficacy.”
The model soon changed shape when applied to other health problems such as seeking
immunization and attempted to more broadly define people's different responses to public health
measures and their use of health services. In these wider applications, the model substituted a
belief in susceptibility to a disease or health problem for the more specific belief that one could
have a disease and not know it, which had been featured in Godfrey Hochbaum's original study
as the most important belief accounting for seeking screening examinations (Breslow &
Cengage, 2002; Champion & Skinner, 2008). The Health Belief Model was selected to inform
the development of the research questions and interpretation of results. See Table 1 for Health
Belief Model constructs and it application to this research of the HPV vaccination.
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Table 1:
Health Belief Model and HPV

Health Belief Model Component

HPV vaccination counterpart

Perceived susceptibility

Knowledge that the patient is at risk for HPV infection.

Perceived severity

Knowledge that HPV can become a serious illness leading to genital
warts, cervical and other cancer.

Perceived benefits

Knowledge that the vaccine reduces risk of
HPV

Perceived barriers

Fear of inadequate reimbursement, inability to complete series, and
parental barriers surrounding the vaccine

Cues to action

Scheduling healthcare visits for the patient to obtain the HPV vaccine
through telephone call back, reminders, and parental education.

Self-efficacy

Confidence in belief that the physician is capable of administering the
HPV vaccine

Summary
The human papillomavirus is the single most common sexually transmitted disease in the
United States (Trottier, 2006). On June 8th, 2006, the FDA approved Gardasil® by Merck
Pharmaceuticals as the first HPV vaccine to protect women between the ages of 9 and 26
(Markowitz et al., 2007). Less than one year later, in 2007, the ACIP of the CDC recommended
that all girls aged 11 and 12 be vaccinated against HPV, with the indication that girls as young as
9 years of age, and older females between the ages of 13 and 26 may receive the vaccine.
On October 16, 2009 the FDA approved the same HPV vaccine, for use in boys and men 9
through 26 years of age for the prevention of genital warts caused by HPV types 6 and 11 and for
offering protection to their partners, making it the only HPV vaccine approved for use in males
at this time. The approved HPV vaccine protects against HPV types 6 and 11 which cause
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approximately 90% of all genital warts cases (MMWR, May 28, 2010). Since there is a high rate
of transmission of HPV in female partners of men with pre-existing warts, and HPV infection in
men has been shown to contribute to HPV infection and subsequent cervical disease and cancer
in women, it is necessary to vaccinate both males and females to prevent the spread of the virus
(Giuliano, 2007).
The National Cancer Institute’s State Cancer Profile reveals Georgia with an estimated 364
new cases of cervical cancer in 2006, with 122 deaths from the disease (State Cancer Profiles,
2010). Despite having this vaccine available, only 38% in Georgia have been vaccinated with at
least one of the three doses that are necessary for HPV immunity (MMWR, 2010). This study
examined the prevalence of Georgia physician intention and administration of the HPV vaccine,
to 11-12 year-old girls and intention to recommend the HPV vaccine, to 11-12 year old boys.
For the purposes of this research, the quadrivalent human papillomavirus vaccine, Gardasil® was
used as it is the only quadrivalent HPV vaccine currently available for commercial use and it is
the only HPV vaccine approved by the VFC program for use in Georgia.
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CHAPTER 2
HYPOTHESES AND RESEARCH QUESTIONS
Research Questions
The following research questions were explored:

Research Question #1:
What barriers do Georgia physicians enrolled in the Vaccine for Children (VFC) program
perceive when providing the Human Papillomavirus Virus (HPV) vaccine to their female
patients?

Research Question #2:
#2:
What knowledge do the Georgia physicians enrolled in the VFC program have when providing
the HPV vaccine to their female patients?

Research Question #3:
What percentage of Georgia physicians enrolled in the VFC program administers the HPV
vaccine to their female patients according to Advisory Committee on Immunization Practices
(ACIP) published guidelines by providing the vaccine to their 11 – 12 year old patients?

Research Question #4:
#4:
What percentage of Georgia physicians enrolled in the VFC program indicates they will
recommend the HPV vaccine to their male patients?

Research Question #5:

What differences will emerge when the data are analyzed by urban vs. rural characteristics?
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Hypotheses
In addition, the following hypotheses were tested:

Hypothesis #1:
No statistical differences will be detected between the perceived barriers by physicians enrolled
in the VFC program who provide the HPV vaccine to females, and geographic setting (urban vs.
rural).

Hypothesis #2:
#2:
No statistical differences will be detected between the perceived knowledge of physicians
enrolled in the VFC program who provide the HPV vaccine to females, and geographic setting
(urban vs. rural).

Hypothesis #3:
#3:
No statistical differences will be detected between the percentage of Georgia physicians enrolled
in the VFC program who administer the HPV vaccine according to ACIP published guidelines
by providing the vaccine to their 11 – 12 year old patients and geographic setting (urban vs.
rural).

Hypothesis #4:
#4:
No statistical differences will be detected between the percentage of Georgia physicians enrolled
in the VFC program who indicate they recommend the HPV vaccine to male patients, and
geographic setting (urban vs. rural).
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CHAPTER 3
METHODS AND MATERIALS
Purpose of the Study
The purpose of this study was to survey Georgia physicians enrolled in the VFC program to
assess their perceived knowledge, barriers, practices and adherence to ACIP guidelines and
recommendations of immunization of the quadrivalent HPV vaccine. The Health Belief Model
(Becker, 1974; Champion & Skinner, 2008; Glanz, Rimer, & Viswanath, 2008; Rosenstock,
1974) was used to inform this study of Georgia vaccine administration in urban and rural
locations.
Design of the Study
The study was approved by the Georgia Southern University Institutional Review Board
prior to data collection in October 2010 (Appendix B). The variables under study, perceived
knowledge, barriers, practices, and adherence to ACIP guidelines were assessed via a crosssectional research design (Campbell & Stanley, 1966). The intent was to provide researchers,
Georgia Department of Community Health and Georgia Public Health with a comprehensive
examination of the status quo with regard to compliance with recommended ACIP guidelines for
vaccine administration in urban and rural locations.
Sampling Plan
The Georgia Immunization Section of the Division of Public Health located within the
Department of Community Health was contacted in January 2010 and a request for a list of VFC
providers who administer the HPV vaccine was submitted. The request was granted by the
acting program director in February 2010. The VFC list included 1,807 providers throughout the
state. Upon examination of the list, it was determined that a physician provider on the list could
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be a single provider practicing at one location or multiple providers practicing at one location. In
addition, it was determined not all provider locations were up to date, and others should be
excluded. Examples of those considered for exclusion included chain grocery stores which had
clinics located within the grocery store and provided influenza vaccines to the general public.
The list was updated in March 2010 with the assistance of the Georgia Immunization Section
within the Division of Public Health to contain only providers who administered vaccine at a
physician setting. The updated list contained 1,307 (N= 1,307) provider practice locations in
each of the 159 counties in Georgia. From this, a stratified sample where type of county was the
strata was created from the VFC provider list. The primary sampling unit was the county.
Counties were selected via probability proportional to size (PPS) sampling. Probabilities for
each county were constructed based on the number of providers within a county, thus counties
with more VFC providers had a higher probability of being selected for inclusion. The
secondary unit of sampling was the provider and all providers within a county were sampled. As
some providers represented more than one physician at a practice location, a question was
included to determine how many physicians were located at that practice location (Appendix C).
The final sampling frame included 389 (n = 389) provider locations. Of these, 305 were located
in six urban counties and 84 were in18 rural counties. An attempt to contact the 389 provider
locations was made. Ninety five responded that they did not give the HPV vaccine in their
office, 30 could not be contacted by telephone or email and 264 responded that they
administered the HPV vaccine in their office yielding a final sampling frame of 264 (n=264).
Instrumentation
The survey of physician perceived knowledge, barriers, practices and adherence to ACIP
guidelines and recommendations of immunization of the HPV vaccine was designed based upon
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previous research. A modification of a previously validated survey tool developed by
researchers from the H. Lee Moffitt Cancer Center and Research Institute (Moffitt) was used.
The Moffitt survey was developed and tested by Vadaparampil and Kahn as part of review of US
physicians and was part of a NIH funded four year project examining physician
recommendations for the quadrivalent human papillomavirus vaccine in 11-12 year old girls,
intention to recommend HPV vaccines to 11-12 year old boys, and attitudes about mandated
HPV vaccination for 11-12 year old girls (Vadaparampil, 2009; Kahn et al., 2009). That survey
was structured to assess constructs identified as being important in predicting physician intention
to recommend HPV vaccines.
The outcome or dependant variables selected for inclusion in the final survey tool pertained
to recommending and administering the HPV vaccine. The first outcome variable was HPV
vaccine recommendation to 9-10 year olds, 11-12 year olds, 13-17 year olds, and 18-26 year
olds. The second outcome variable is likelihood of recommending the HPV vaccine to 11-12
year old boys and the third outcome variable was agreement with mandated ACIP guidelines of
vaccinating 11-12 year old girls.
The final survey tool developed for this research included 23 questions that were Yes/No,
True/False, and Likert-type responses (Appendix D). The final survey question was open ended.
This question allowed respondents the opportunity to share any information or valuable lessons
learned about adopting a new vaccine into their practice. Participants were asked to identify
responses that best match with their perceived knowledge, barriers, practices, and adherence to
the ACIP guidelines and recommendations. All questions pertained to the quadrivalent HPV
vaccine Gardasil® and did not include questions on other vaccines. This decision was made
because Gardasil® is the only vaccine allowed under the VFC program at this time.
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The first section of the survey tool accessed physician HPV knowledge, valued sources of
information about HPV vaccines, educational needs related to HPV vaccines, barriers to HPV
vaccination, frequency of HPV vaccine recommendation and administration to girls in four age
groups (9-10, 11-12, 13-17, and 18-26 years) and intention to recommend the HPV vaccine to
boys in the same four age groups.
Physician knowledge about the HPV vaccine was measured with the use of seven items.
These were: assessing HPV medical intervention, treatment of HPV, causes of genital warts and
cervical cancer, FDA approval, and if a previous diagnosis of HPV precluded immunization.
Physician and parental barriers to HPV vaccination were assessed through 12 Likert-type scale
items.
Practice characteristics included whether the physician cared for women in different age
groups, patient demographic characteristics, patients’ insurance coverage, primary physician
specialty, type of practice (Pediatric, Family Medicine, Internal Medicine,
Obstetrics/Gynecology, Academic or other),and practice location (urban or rural). Two
questions explored physician vaccination adoption style.
The remaining section of the survey contained demographic questions on the physician’s
age, gender, and ethnicity. All questions were quantitative in nature except the final question
which was open-ended. This question allowed respondents the opportunity to share any
information or valuable lessons learned about adopting a new vaccine into their practice. The
qualitative data did not receive in-depth analysis, but was used to enhance findings and to be of
use to others who wish to offer a new vaccine or increase their rates of immunization. The
variables included in this research are described in Table 2.
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Table 2:
Study Variables Description and Variable Type - HPV
VARIABLE

DESCRIPTION

VARIABLE TYPE

Administration of HPV
vaccine to girls

Intramuscular injection of the HPV vaccine to a
female between the ages of 9 and 26 years

Outcome Variable

Recommendation of HPV
vaccine to boys

Recommending the HPV vaccine to male
patients between the ages of 11 and 12 years.

Outcome Variable

Administration of HPV
vaccine according ACIP
guidelines

Intramuscular injection of HPV vaccine to
female between the ages of 11 and 12 years

Outcome Variable

Georgia County – Urban

County with > or = 35,000 population

Independent Variable

Georgia County – Rural

County with < 35,000 population

Independent Variable

Sources of Information

Professional Organization
ACIP guidelines
State and local immunization programs
Colleagues
Pharmaceutical representatives
Internet websites
Media
Medial conference
Grand rounds
Local institutional lectures
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Independent Variables

Table 2.
(Continued) Study Variables Description and Variable Type - HPV
VARIABLE
Barriers to HPV
vaccination

DESCRIPTION
•
•
•
•
•
•

•
•
•
•
•
•
•

VARIABLE TYPE

Vaccine safety to the patient
Vaccine efficacy against HPV
Discussing sexuality/sexually transmitted
infections with child or parent by physician
Administering a new vaccine with limited
track record of safety
Adding another vaccine to vaccine
schedule
Lack of information about the
Quadrivalent HPV vaccine by child or
parent
Cost of purchasing the vaccine (upfront
cost to physician)
Cost of stocking HPV vaccine to the
physician
Lack of adequate reimbursement for HPV
vaccine to physician
Failure of some insurance companies to
cover the cost of HPV vaccine
Time to discuss HPV vaccination with
patients and/or parents by physician
Difficulty ensuring patient will complete
the 3 dose HPV vaccination series
HPV vaccination is not required for school
attendance in Georgia
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Independent Variable

Table 2.
(Continued) Study Variables Description and Variable Type - HPV
VARIABLE

DESCRIPTION
•

Knowledge about HPV
•

•
•

•

•

•

Clinic specialty

Physician knowledge that most HPV
infections resolve without medical
intervention
Physician knowledge that HPV is a
relatively common sexually transmitted
infection
Physician knowledge that HPV causes
genital warts in males and females
Physician knowledge that almost all
cervical cancers are caused by HPV
infection
Physician knowledge that FDA approved
the quadrivalent HPV vaccine for use in
females ages 9-26
Physician knowledge that females who
have been diagnosed with an HPV
infection may still receive the vaccine
Physician knowledge that the FDA
approved the quadrivalent HPV vaccine for
use in males for permissive use for ages 926

Categorical variable of
•
•
•
•
•
•

Practice characteristics

VARIABLE TYPE

Independent Categorical

Pediatrics
Family Medicine
Internal Medicine
Obstetrics/Gynecology
Academic
Other

Categorical variable of
•
•
•

Independent Variable

Variable

Independent Categorical

Single Specialty
Multispecialty
Other

Variable
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Table 2.
(Continued) Study Variables Description and Variable Type - HPV
VARIABLE

DESCRIPTION

VARIABLE TYPE

Number of physicians in
practice

Categorical variable of
• 1
• 2-5
• 6-9
• 10-14
• 15-25
• > 25

Independent Categorical Variable

Race/Ethnicity of
physician

Categorical variable of
• White/Caucasian
•
Asian
• Native Hawaiian/Pacific Islander
• Black/African-American, American
• Indian/Alaska Native
• Mixed Race
• Other,

Years in practice since
Residency

Categorical variable classifying number of years
since medical residency training

Independent Categorical Variable

Type of insurance

Categorical variable of
• Private insurance
•
Medicaid,
• PeachCare (state insurance for low
income children)
• Uninsured/Self pay
• Medicare
• Other

Independent
Categorical Variable

Age of Physician

Categorical variable of the physician’s age at the
time of survey

Independent Categorical Variable

Gender of Physician

Categorical variable of
• Male
• Female

Independent Categorical Variable

Independent Categorical Variable

Collection and Treatment of Data
Data collection occurred between December 2010 and February 2011. Three steps were used
to collect data (Table 3). In step one, key informants such as physicians, immunization nurses or
office managers at each physician location were identified to determine the size of the practice
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and who would complete the survey. At this stage, an electronic format for respondents (i.e.,
Survey Monkey) was created and uploaded onto a dedicated webpage. In step two, the
physician or key informant who would respond to the survey for the physician was contacted to
obtain his/her agreement to participate in the study. This was to inform participants about the
internet survey site and to verify that all contact information (i.e., electronic/postal mail
addresses and phone numbers) was correct. The third step involved second, third, and fourth
survey mailing, postal mailing and follow-up phone calls (Appendices E, F, G, and H). An offer
to complete a telephone survey with non-responders to maximize response rate was initiated
during the month of January and occurred after the third phone call (Appendix I). Phone calls
continued until all participants responded, or until the scheduled date for survey completion
arrived – February 7, 2011.
Table 3:
Survey Timetable
Date

Activity

August/September 2010

Key information on Georgia physicians participating in VFC program
identified

October 20 – 30, 2010

Survey Monkey format created for key informant survey

November 1, 2010

Survey posted to internet link

November 8, 2010

Phone calls and mail to physician responders begins

January 3 – January 31 2011

Follow-up phone calls and mail to non-responders

Week of February 7, 2011

Deadline for survey completion

Week of February 14, 2011

Data entry begins
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Analysis and Interpretation of the Data
A survey instrument was administered to a sample of Georgia physicians in 14 public health
districts in six urban and 18 rural counties. The survey was sent to the sample of 264 providers.
Respondents were asked about their knowledge of the vaccine and if they administered the
vaccine according to ACIP guidelines by offering it to females at 11-12 years of age and if they
recommend it to males according to ACIP guidelines of “permissive use.” Respondents were
also asked to respond to barriers they perceived to be associated with this vaccine.
A final qualitative question was open-ended and allowed respondents to comment on their
experience with the vaccine. Prevalence data were created for all dependent measures to
determine the percentage of perceived knowledge, barriers, practices, and adherence to ACIP
guidelines where appropriate. The qualitative data did not receive an in-depth analysis, but were
used to augment findings and to record what may be useful to other providers and others who
wish to offer a new vaccine or increase rates of immunization.
Quantitative data analysis was performed using SAS. Data came from a complex
probability sample, and was summarized and analyzed using the SAS procedures, SurveyFreq,
SurveyMeans, SurveyReg and SurveyLogistic. SAS procedure SurveySelect was used to help
select the sample using a PPS without replacement design. As the data were the result of a
complex probability based survey, results for strata and domains were generally presented in
terms of confidence intervals which provide the most meaningful analysis. A logistic regression
analysis was performed to determine what may influence a physician’s decision to not
recommend (dependent variable) HPV vaccine while payer type, physician barriers, and parental
barriers served as the independent variables.
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CHAPTER 4
RESULTS
The purpose of this study was to examine the prevalence of Georgia physician intention and
administration of the HPV vaccine to 11-12 year-old girls and intention to recommend the HPV
vaccine to 11-12 year old boys. The study accessed perceived knowledge, barriers, practices,
and adherence to ACIP guidelines and recommendations regarding HPV vaccination. The
Health Belief Model (Champion & Skinner, 2008; Glantz, et al., 2008) was used to guide this
study of Georgia physicians.
This chapter is organized into the following sections to present study results: (1) sample
characteristics; (2) descriptive analysis of survey questions; (3) descriptive analysis for variables;
(4) analysis of the research questions and hypotheses and analysis of variables associated with
not recommending the HPV vaccine.
Sample Characteristics
A stratified single stage 100% cluster sample with counties being the cluster was performed.
Two strata were formed, urban and rural. Sampling weights for the clusters were computed
based on the number of providers within the county. The number of providers within a county
divided by the number of providers in the state was the probability of a county being selected.
The sampling weight is the inverse of the probability of selection. Once a cluster was selected
then all providers within that county were included in the survey (hence 100% cluster sample).
All computations were performed using SAS Proc SurveyMeans, Proc SurveyFreq and Proc
SurveyLogistic.
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The initial sampling frame included 389 (N = 389) provider locations. Of these, 305 were
located in six urban counties and 84 were in18 rural counties. Of the 389 physicians, 264
(67.9%) responded to telephone contact and stated they administered the HPV vaccine, 95
(24.4%) stated they did not administer the HPV vaccine and 30 (7.7%) were unable to be
contacted by telephone or postal mail.
Of the 264 who administered the HPV vaccine, 62 (23.5%) were in 18 rural counties located
in ten public health districts and 202 (76.5%) were in six urban counties located in ten public
health districts. These 264 providers served as the study’s population for HPV survey
administration (n=264).
There were 42 physician locations (17.4%) that did not respond to the request to take part in
the survey. Thirty eight (14.4%) of the 42 stated their refusal to participate when contacted and
the remaining eight (3%) could not be contacted by telephone or postal mail. There were 218
physicians or key informants who could represent the physician in the Georgia study population
who positively responded to the survey questionnaire yielding a response rate of 82.6%. Of the
218 respondents, 15 (6.8%) responded through Survey Monkey, 72 (33%) responded though the
postal mail and 131 (60.1%) responded by telephone survey. Table 4 displays the method by
which the 214 physicians responded to the survey questionnaire.
Table 4:
Method by Which Physicians Responded to Survey

Variable

Survey Monkey
Postal Mail survey
Telephone survey
Responded to survey
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n

Percent

15
72
131

5.7
33
60.1

218

100

Demographic variables of the respondents were obtained; however, not all respondents
answered all questions in the survey. The variables of race, ethnicity, gender, and years in
practice were included in the survey. Respondents were predominantly white (109 or 51.4%)
followed by Asian respondents (48 or 22.6%) followed by African American (39 or 18.4%).
There were 10 (7.3%) who preferred not to answer and seven (3.3%) who listed their race as
other. Six of the 218 did not respond to this question.
Most respondents (190 or 90.5%) self identified as non Hispanic or Latino. Two hundred ten
(96.3%) responded to the question of gender with slightly more male’s (107 or 51%) than
female’s (103 or 49%). Forty four physicians (25%) had been in practice 0-9 years, followed by
65 (36.9%) in practice from 10-19 years. Forty-one physicians (23.3%) had been in practice 20 –
29 years and 26 (18.8%) had been in practice for 30 years or more. Table 5 displays the
demographic characteristics.
Table 5:
Physician Demographic Characteristics
Variable

n

Percent

109
48
39
10
7

51.4
22.6
18.4
4.7
3.3

Responded to question (one responded in two categories)
Hispanic/Latino
Identified as Hispanic or Latino
Did not identify as Hispanic or Latino

212

100%

20
190

9.5
90.5

Responded to question
Years in Practice
0-9 years
10-19 years
20-29 years

210

100%

44
65
41

25
36.9
23.3

Race
White
Asian
Black or African American
Prefer not to answer
Other
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Variable

n

Percent

26

18.8

Responded to question
Physician Gender
Male
Female

176

100%

107
103

51%
49%

Responded to question

210

100%

>30 years

Information on physician practice variables was obtained. The majority of respondents
(182 or 85%) were in a single practice specialty, followed by 27 (12.7%) in multi-specialty
practices. Three (1.4%) respondents listed other for practice characteristics. These were
Federally Qualified Health Clinics or medical clinics associated with a teaching hospital with
physician oversight.
Two hundred thirteen responded to the question on primary clinical practice specialty. Sixty
eight (31.9%) identified their specialty as Family Medicine, seven (3.3%) identified as Internal
Medicine, and seven (3.3%) identified as Obstetricians/Gynecologists. The majority (126 or
59%) identified as pediatricians. Approximately 2.3% self identified as other.
Most physicians (102 or 47.9%) were in a solo practice, meaning they were the only
physician in their respective practices. Ninety-two (43.2%) were in practice with as many as four
other physicians. Ten (4.7%) respondents practiced with six to nine other physicians. Five
(1.4%) were in practice with as many as 25 other physicians and one practice (0.5%) reported
over 26 physicians. For the purposes of this research, resident physicians, nurse practitioners
and physician assistants working with the physician were excluded.
Reimbursement in various forms was accepted by most physicians. Of the 206 who
responded to this question, private insurance and Medicaid was accepted by all physicians at
practice locations. The Georgia Children’s Health Insurance or PeachCare was accepted by 202
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physicians (98%). Uninsured or patients paying for services themselves were accepted by 204
physicians (99%) and Medicare was accepted by 195 physicians (94.6%). Other forms of
payment (such as military reimbursement) were accepted by 81.5% of physicians.
Urban or rural classification was coded by the researcher after all surveys were submitted.
Using the definition from by the Georgia Office of Rural Health (2002), 176 physicians (80.7%)
practiced in an urban county and 42 (19.3%) practiced in a rural county. If the physician or key
informant completing the survey questionnaire for the physician had a practice in more than one
location, the respondent was asked to complete the survey by answering questions as if it
pertained only to that practice location. For example, if the physician gave HPV vaccine to
males at one location but did not administer the vaccine at the location that received the survey,
the physician or key informant was asked to answer survey questions at it pertained to the
location that received the survey. Table 6 displays demographic variables of the physician’s
practice.
Table 6:
Physician Practice Demographic Characteristics
Variable
Practice Characteristics
Single specialty
Multi specialty
Other

n

Percent

182
27
3

85.8
12.7
1.4

Responded to question
Practice Classification
Family Medicine
Internal Medicine
Obstetrics/Gynecology
Pediatrics
Other

212

100%

68
7
7
126
5

31.9
3.3
3.3
59.2
2.3

Responded to question

213

100

53

Variable

n

Percent

Physicians at Location
1
2-5
6-9
10-14
15-25
> 26

102
92
10
3
5
1

47.9
43.2
4.7
1.4
2.3
0.5

Responded to question

213

100

Reimbursement Accepted by Practice
Private insurance
Medicaid
PeachCare of Georgia
Uninsured/Self-pay
Medicare
Other (example: Military)

206
206
202
204
195
168

100
100
98
99
94.6
81.5

206

100

Responded to question
County classification
Urban
Rural

176
42

80.7
19.3

Coded by researcher

218

100%

Descriptive Analysis of Survey Questions
Nine items assessing valued sources of information about HPV vaccine are shown in Table
7. Most of the 215 respondents (94.4%) indicated professional organization was a source of
information on HPV vaccine. The ACIP as a source was reported by 92.1%). State and local
immunization programs were noted by 197 respondents (92.5%) and information from the HPV
pharmaceutical representatives (92.5%) was a reported source of HPV information. Going to
colleagues (86.4%), internet websites (81.5%), and medical conferences (77.9%) were not as
valued. Least valued were media sources (44.1%) and grand rounds or location institution
lectures (27.2%) by respondents.
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Table 7:
Sources of Information
Variable

n

Percent

Valuable sources of information about HPV vaccination
Professional Organizations (e.g., AAFP, ACOG, AAP, SGIM)
Advisory Council of Immunization Practice (ACIP)
State and local immunization programs
Colleagues
Pharmaceutical representative
Internet websites
Media
Medical conferences
Grand rounds/local institutional lectures

203
198
197
184
197
174
94
166
58

94.4
92.1
92.5
86.4
92.5
81.5
44.1
77.9
27.2

Responded to question

215

100%

Seven items assessing knowledge about HPV vaccine were determined. Of the 214
respondents, 164 (76.7%) knew HPV infections resolved without medical intervention, 184
(86.4%) knew HPV was a common sexually transmitted disease, and 192 (90.6%) knew HPV
caused genital warts in males and females. The FDA approval of the vaccine for use in females
ages 9-26 was known by 208 (97.2%) while 169 (79.3%) knew that a previous HPV infection did
not preclude a female from being vaccinated. Lastly, the FDA approval of the vaccine for males
for permissive use for ages 9-26 years was known by 200 (94.8%) of the respondents. The seven
items assessing knowledge about HPV vaccine are shown in Table 8.
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Table 8:
Knowledge About HPV
Variable
Knowledge items (correct)
Most HPV infections resolve without medical interventions
HPV is a relatively common sexually transmitted disease
HPV causes genital warts in males and females
Almost all cervical cancers are caused by HPV infection
The FDA approved the quadrivalent HPV vaccine for use in
females ages 9-26
Females diagnosed with HPV infection can be given the vaccine
The FDA approved the quadrivalent HPV vaccine for use in
males ages 9-26
Responded to question

n

Percent

164
184
192
195
208

76.7
86.4
90.6
91.1
97.2

169
200

79.3
94.8

214

100%

Barriers to vaccination attributed to the physician were assessed through 12 items. The
responses of sometimes, often and always were summed to achieve the number of physicians
who perceived these as barriers to administering the HPV vaccine. A total of 212 responded as
illustrated in Table 9. Of those who responded, 21 (9.9%) were concerned about vaccine safety
and 22 (10.3%) were concerned about the efficacy of the HPV vaccine. Administering a new
vaccine with a limited track record of safety was a barrier to 32 physicians (15.1%) and 22
physicians (10.3%) believed adding another vaccine to the vaccine schedule was a barrier. Lack
of information about the vaccine was perceived as a barrier by 12.7% of the respondents.
The initial cost, or upfront cost of purchasing the vaccine was considered a barrier among
129 respondents (60.8%) and 134 respondents (63.2%) believed cost of stocking the vaccine to
be a barrier to their practice. Lack of adequate reimbursement for the vaccine was considered a
barrier among 136 respondents (64.2%) and failure of some insurance companies to cover the
cost of vaccination was a barrier among 126 respondents (59.4%). Only 40 respondents (18.7%)
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considered the time it takes to discuss the vaccine with parents or patients to be a barrier.
Moreover 90 respondents (42.5%) believed that ensuring the completion of the 3-dose series to
be a barrier. HPV vaccination not being a requirement for school attendance was perceived to be
a barrier among 15.1% of those responding.
Table 9:
Barriers to HPV Vaccination – Physician
Variable

n

Percent

Barriers related to immunizing against HPV
Concerns about vaccine safety
Concerns about vaccine efficacy
Administering a new vaccine with a limited track record of safety
Adding another vaccine to the vaccine schedule
Lack of information about the vaccine
Up front cost of purchasing private stock vaccine
Cost of stocking the vaccine
Lack of adequate reimbursement for the vaccine
Failure of some insurance companies to reimburse the vaccine
Time to discuss the vaccine with parents and/or patients
Difficulty ensuring 3-dose vaccine compliance
Vaccine is not required for school attendance

21
22
32
22
27
129
134
136
126
40
90
34

9.9
10.3
15.1
10.3
12.7
60.8
63.2
64.2
59.4
18.7
42.5
15.1

Responded to the question

212

100

Twelve barriers to vaccination attributed to the parent were assessed. The responses of
sometimes, often, and always were summed to achieve the number of physicians who perceived
these to be barriers recognized by the parent as not allowing the male or female child to be
vaccinated. A total of 208 physicians, or key informants, who responded as the physician,
completed this section. Of those who responded, 137 (65%) believed the parent had concerns
about vaccine safety and 78 respondents (37.5%) believed the parent had concerns about vaccine
efficacy. A larger group (77.9%) believed parents were reluctant to discuss sexuality or sexually
transmitted infections, while 145 respondents (69.7%) indicated parental concerns that their child
would assume approval of premarital sex if the parent agreed to vaccination. Lack of parental
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education or understanding about the vaccine was given by 173 respondents (84.3%) and 168
respondents (80.8%) believed the parent thought their child was not at risk for HPV infection.
Parental consent to vaccination was not considered a significant barrier and was given by 121
respondents (58.2%). Parent opposition to HPV vaccination for moral or religious reasons
appeared to be the least important barrier as indicated by 53 respondents (25.5%). Physicians
who believed parents thought their child was too young for vaccination numbered 168 (80.8%)
and parental concern about negative media reports related to the HPV vaccine was low (40.4%).
Table 10 displays parental barrier variables to HPV vaccine.
Table 10:
Barriers to HPV Vaccination - Parental
Variable
Barriers related to immunizing against HPV
Concerns about vaccine safety
Concerns about vaccine efficacy
Reluctance to discuss sexuality/sexually transmitted infections
Concern adolescent will assume that parent who agrees to
vaccination condones premarital sex
Concern vaccinated child will practice riskier sexual behaviors
Lack of education/understanding of HPV infection
Request that vaccination be deferred
Belief that adolescent is not a risk for HPV infection
Will not consent to vaccination
Opposition to vaccination for moral or religious reasons
Belief that adolescent is too young for vaccination
Concern about negative media reports related to vaccine
Responded to the question

n

Percent

137
78
162
145

65
37.5
77.9
69.7

144
173
187
168
121
53
168
84

69.2
83.2
89.9
80.8
58.2
25.5
80.8
40.4

208

100

Respondents were asked if they recommended the HPV vaccine, as well as the patient’s age
when the recommendation was made. Responses are profiled in Table 11. Of the 209 who
responded for 9-10 year old females, 58 (27.8%) reported they never offer the vaccine at this
age, 57 (27.3%) offered it rarely and 30 (14.4%) indicated they sometimes offered the vaccine.
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Twenty-three (11.0%) reported they offered the vaccine often and 34 (16.3%) reported they
always offered the HPV vaccine to female patients in this age group. Seven (3.3%) responded
they did not see patients in this age group.
Of the 210 who responded regarding their 11-12 year old female patients, 10 (4.8%)
reported they never offer the vaccine at this age, 30 respondents (14.3%) offered it rarely and 19
respondents (9.0%) sometimes offered the vaccine. Forty respondents (19.0%) reported they
offered the vaccine often and 106 (50.5%) reported they always offered the HPV vaccine to
female patients in this age group. Five respondents (2.4%) indicated they did not see patients in
this age group.
Of the 209 who responded regarding their 13-17 year old females, none (0%) reported they
never offer the vaccine at this age indicating they offer the vaccine to females at this age. Only 2
(1%) did so rarely and 17 (8.1%) responded they sometimes offered the vaccine. Forty-four
respondents (21.1%) reported they offered the vaccine often and 50.5% of respondents reported
they always offered the HPV vaccine to female patients in this age group. Five (2.4%)
responded they did not see patients in this age group.
Of the 207 who responded for 18-26 year old females, none (0%) reported they never offer
the vaccine indicating they offer to all females at this age. Only 4 (1.9%) did so rarely and 15
(7.2%) responded they offered the vaccine sometimes. Thirty-three (15.9%) reported they
offered the vaccine often and 53.6% physicians reported they always offered the HPV vaccine to
female patients in this age group. Forty-four (21.3%) responded they did not see patients in this
age group.
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Table 11:
Recommend HPV Vaccine to Girls by Age Group
9-10 y
--------n (%)
Never (never recommend)
Rarely (recommend 1-25%)
Sometimes (recommend 26-50%)
Often (recommend 51-75%)
Always (recommend >76%)
Do not see patients in this age group
Responded to question

58 (27.8)
57 (27.3)
30 (14.4)
23 (11.0)
34 (16.3)
7 (3.3)
209

11-12 y
--------n (%)

13-17 y
--------n (%)

18-26 y
--------n (%)

10 (4.8)
30 (14.3)
19 (9.0)
40 (19.0)
106 (50.5)
5 (2.4)

0 (0.0)
2 (1.0)
17 (8.1)
44 (21.1)
146 (69.9)
0 (0.0)

0 (0.0)
4 (1.9)
15 (7.2)
33 (15.9)
111 (53.6)
44 (21.3)

210

209

207

Respondents were then asked at what age they administered at least one dose of HPV
vaccine to their female patients. Responses to this question are illustrated in Table 12. Of the
210 who responded for 9-10 year old females, 79 (37.6%) reported they never administer the
vaccine at this age, approximately one-third (33.8%) did so only rarely and 31 (14.8%)
responded they offered the vaccine sometimes. Sixteen (7.6%) reported they offered the vaccine
often and 34 (16.3%) reported they always administered the HPV vaccine to female patients in
this age group. Seven (3.3%) responded they did not see patients in this age group.
Of the 209 who responded for 11-12 year old females, 17 (8.1%) reported they never
administered the vaccine to female patients at this age, 48 respondents (23%) did so only rarely
and 51 respondents (24.4%) indicated they administered the vaccine sometimes. Approximately
one-third (30.1%) reported they administered the vaccine often and 25 respondents (12%)
indicated they always administered the HPV vaccine to female patients in this age group. Five
respondents (2.4%) indicated they did not see patients in this age group.
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Of the 210 who responded for 13-17 year old females, none (0%) reported they never
administered the vaccine at this age indicating all respondents administer to females at this age.
Although 10 respondents (4.8%) indicated they offered it rarely and approximately one-third
(31.9%) responded they administered the vaccine sometimes. Eighty-five (40.5%) reported they
administered the vaccine often and 106 (50.5%) reported they always administered the HPV
vaccine to female patients in this age group. Five (2.4%) responded they did not see patients in
this age group.
Of the 208 who responded for 18-26 year old females, none of the physicians (0%) reported
they never administered the vaccine indicating all administer the vaccine to all females at this
age. Fourteen (6.7%) did so rarely and approximately one-fourth (24%) responded they offered
the vaccine sometimes. Approximately one-third (32.7%) reported they offered the vaccine
often and 34 physicians (16.3%) reported they always offered the HPV vaccine to female
patients in this age group. Forty-two (20.2%) responded they did not see patients in this age
group.
Table 12:
Administer HPV to Girls by Age Group

Never (never administered)
Rarely (administered 1-25%)
Sometimes (administered 26-50%)
Often (administered 51-75%)
Always (administered >76%)
Do not see patients in this age group
Responded to question

9-10 y
--------n (%)

11-12 y
--------n (%)

13-17 y
--------n (%)

79 (37.6)
71 (33.8)
31 (14.8)
16 (7.6)
6 (2.9)
7 (3.3)

17 (8.1)
48 (23.0)
51 (24.4)
63 (30.1)
25 (12.0)
5 (2.4)

0 (0.0)
10 (4.8)
67 (31.9)
85 (40.5)
48 (22.9)
0 (0.0)

210

209
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210

18-26 y
--------n (%)
0 (0.0)
14 (6.7)
50 (24.0)
68 (32.7)
34 (16.3)
42 (20.2)
208

Parental refusal to allow their daughters to be vaccinated is a barrier. Respondents were then
asked if parents refused to allow their daughters to be vaccinated when the physician offered or
recommended the HPV vaccine, and at what age did refusal occur. Responses are illustrated in
Table 13. Of the 202 who responded for 9-10 year old females, seven physicians (3.5%)
reported they never experienced a parent who refused to have their daughter vaccinated with the
HPV vaccine once it was offered. Twelve (5.9%) indicated this occurred only rarely and 41
(20.3%) responded this sometimes. Over one-fourth (25.7%) reported they experienced this
often and 83 (41.1%) reported they always experienced refusal with this age group. Seven
(3.3%) responded they did not see patients in this age group.
Of the 205 who responded for 11-12 year old females, three physicians (1.5%) reported they
never experienced a parent who refused to have their daughter vaccinated with the HPV vaccine
once it was offered. Thirty-eight (18.5%) indicated this occurred only rarely and 88 (42.9%)
responded this occurred sometimes. Over one-fourth (25.4%) reported they experienced this
often and only 19 physicians (9.3%) reported they always experienced refusal with this age
group. Five (2.4%) responded they did not see patients in this age group. Of the 208 who
responded for 13-17 year old females, seven physicians (3.4%) reported they never experienced
a parent who refused to have their daughter vaccinated with the HPV vaccine once it was
offered. Approximately one-third (34.1%) indicated vaccine refusal occurred only rarely and
over half (55.8%) responded this occurred sometimes. Twelve respondents (5.8%) reported they
experienced vaccine refusal occurred often and few (1.0%) reported they always experienced
refusal with this age group.
Of the 207 who responded for 18-26 year old females, eight physicians (3.9%) reported they
never experienced a parent who refused to have their daughter vaccinated with the HPV vaccine
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once it was offered. Approximately one-third (30%) indicated this occurred only rarely and 86
(41.5%) responded this occurred sometimes. Seven (3.4%) reported they experienced this often
and few (1.0%) reported they always experienced refusal with this age group. Forty-two
physicians (20.3%) did not see female patients in this age group.
Table 13:
Parental Refusal of HPV Vaccine to Girls by Age Group

Never (never refused)
Rarely (refused 1-25%)
Sometimes (refused 26-50%)
Often (refused 51-75%)
Always (refused >76%)
Do not see patients in this age group
Responded to question

9-10 y
--------n (%)

11-12 y
--------n (%)

13-17 y
--------n (%)

7 (3.5)
12 (5.9)
41 (20.3)
52 (25.7)
83 (41.1)
7 (3.5)

3 (1.5)
38 (18.5)
88 (42.9)
52 (25.4)
19 (9.3)
5 (2.4)

0 (0.0)
10 (4.8)
67 (31.9)
85 (40.5)
48 (22.9)
0 (0.0)

202

205

18-26 y
--------n (%)
0 (0.0)
14 (6.7)
50 (24.0)
68 (32.7)
34 (16.3)
42 (20.2)

208

207

The ACIP recommends optional HPV vaccination for males to protect them from genital
warts, although the ACIP stopped short of recommending routine use in males. Of the 211 who
responded for 9-10 year old males, 86 physicians (40.8%) reported they never recommend their
male patients receive the HPV vaccine. Forty-nine (23.2%) did so only rarely and 23 (10.9%)
responded they offered the vaccine sometimes. Twenty-two (10.4%) reported they offered the
vaccine often and 23 (10.9%) reported they always offered the HPV vaccine to male patients in
this age group. Eight (3.4%) responded they did not see patients in this age group.
Of the 211 who responded regarding their 11-12 year old male patients, 49 respondents
(23.2%) reported they never offer the vaccine at this age, 34 respondents (16.1%) did so only
rarely and 29 respondents (13.7%) indicated they offered the vaccine sometimes. Forty-one
(19.4%) reported they offered the vaccine often and 50 (23.7%) reported they always offered the
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HPV vaccine to male patients in this age group. Eight (3.8%) responded they did not see patients
in this age group.
Of the 208 who responded regarding their 13-17 year old males, 37 (17.8%) reported they
never offer the vaccine at this age. Thirty-two (15.4%) did so rarely and 34 (16.3%) responded
they offered the vaccine sometimes. Forty-two (20.2%) reported they offered the vaccine often
and slightly over one-fourth (26.9%) reported they always offered the HPV vaccine to male
patients in this age group. Seven (3.4%) responded they did not see patients in this age group.
Of the 210 who responded for 18-26 year old males, 29 physicians (13.8%) reported they
never offer the vaccine to all males at this age. Thirty-three physicians (15.7%) did so rarely and
25 (11.9%) responded they offered the vaccine sometimes. Thirty (14.3%) reported they offered
the vaccine often and 47 physicians (22.4%) reported they always offered the HPV vaccine to
male patients in this age group. Forty-six (21.9%) responded they did not see patients in this age
group. Responses are profiled in Table 14.
Table 14:
Recommend HPV Vaccine to Boys by Age Group

Never (never recommend)
Rarely (recommend 1-25%)
Sometimes (recommend 26-50%)
Often (recommend 51-75%)
Always (recommend >76%)
Do not see patients in this age group
Responded to question

9-10 y
--------n (%)

11-12 y
--------n (%)

13-17 y
--------n (%)

86 (40.8)
49 (23.2)
23 (10.9)
22 (10.4)
23 (10.9)
8 (3.8)

49 (23.2)
34 (16.1)
29 (13.7)
41 (19.4)
50 (23.7)
8 (3.8)

37 (17.8)
32 (15.4)
34 (16.3)
42 (20.2)
56 (26.9)
7 (3.4)

211

211
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208

18-26 y
--------n (%)
29
33
25
30
47
46

(13.8)
(15.7)
(11.9)
(14.3)
(22.4)
(21.9)
210

Analysis of Research Questions and Hypotheses
Research Question #1
What barriers do Georgia physicians enrolled in the Vaccine for Children (VFC)
program perceive when providing the Human Papillomavirus Virus (HPV) vaccine to
their female patients?

For those physicians that responded, 64.2% believed the most important barrier for not
vaccinating was lack of adequate reimbursement for HPV vaccination. This was followed by
63.2% citing the cost of stocking the HPV vaccine, 60.8% believed the upfront or initial cost of
purchasing the private stock HPV vaccine, and 59.4% believed the failure of some insurance
companies to cover the cost of the vaccine was a barrier. Difficulty ensuring that patients will
complete the 3-dose HPV vaccination series was cited as a barrier by 42.5% of respondents.
Barriers dropped sharply with 18.7% indicating the time it takes to discuss HPV vaccination with
patients and or parents as a barrier. Administering a new vaccine with a limited track record of
safety was a barrier to only 15.1% of respondents and lack of information was a barrier to 12.7%
of respondents. Adding another vaccine to the vaccine schedule and concerns about efficacy of
the HPV vaccine was a barrier to 10.3% respectively. Only 9.9% had concerns about the safety
of the HPV vaccine.
The most significant parental barrier to vaccination according to physicians was the request
that HPV vaccine be deferred until the female patient was older. This barrier was noted by
89.9% of respondents followed by lack of education/understanding of the HPV vaccine (83.2%).
Physicians noted parental belief that the daughter was too young and the barrier that they
believed the daughter was not at risk for HPV infection were 80.8% respectively. Reluctance to
discuss sexuality or sexually transmitted infections by the parent was 77.9%. This was followed
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by 69.7% believing parental concern that the adolescent assumed parents who agree to HPV
vaccination condone premarital sex. Slightly more than two-thirds or 69.2% believed parent has
concerns that the vaccinated adolescent would practice riskier sexual behaviors. Parental
concern about vaccine safety was noted by 65% of the respondents. Refusal to consent to have
the adolescent vaccinated was a barrier of 58.2% respondents. Parental concerns about negative
media reports related to the HPV vaccine was a barrier to only 40.4% and parental concern about
vaccine efficacy was a concern to 37.5%.
In summary, barriers to HPV vaccination for physicians focused on the cost of purchasing
and storing the vaccine by the physician and lack of adequate reimbursement. The physician
time it takes to talk about or educate about the vaccine was viewed as less of a barrier. The least
mentioned barrier was parental opposition to HPV vaccination for moral or religious reasons.
The most important barrier for parents toward HPV vaccination was the parental request that
vaccination be deferred. This barrier was followed by lack of education or understanding of the
vaccine. Many physicians cited as a common barrier the parents’ belief that their female child
was not a risk for HPV infection.
Research Question #5:
What differences will emerge when the data are analyzed by urban vs. rural
characteristics?

To answer research question #5, Hypothesis #1 was tested.
Hypothesis #1:
No statistical differences will be detected between perceived barriers by physicians
enrolled in the VFC program who provide the HPV vaccine to females and geographic
setting (urban vs. rural).
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Due to missing cells in the response categories, tests of hypothesis could not be performed,
however estimates of proportions and their standard errors were calculated and no statistical
significance was detected between perceived barriers by physicians enrolled in the VFC program
that provide the HPV vaccine to females, and geographic setting. Estimates of proportions and
their standard errors to physician perceived barriers are listed in Table 15 and estimates of
proportions and their standard error to parental barriers are listed in Table 16. Since confidence
intervals were overlapping across response categories between urban and rural practice setting,
no statistical differences were detected
Table 15:
Responses to Question #3

Concern about
vaccine safety
Q3A Rural
Q3A Urban
Concern about
vaccine efficacy
Q3B Rural
Q3B Urban
Administering a new
vaccine with limited
safety track record
Q3C Rural
Q3C Urban
Adding another
vaccine to schedule
Q3D Rural
Q3D Urban
Lack of information
about the vaccine
Q3E Rural
Q3E Urban

Strongly
Disagree

Somewhat
Disagree

Neutral

Somewhat
Agree

Strongly Agree

.4
(.317, .484)
.442
(.326, .558)

.4
(.316, .483)
.255
(.17, .341)

.18
(.103, .257)
.19
(.096, .284)

.02
(0, .053)
.109
(.042, .176)

0
.003
(.0, .007)

.381
(.297, .464)
.407
(.292, .521)

.4
(.33, .47)
.289
(.196, .381)

.18
(.11, .25)
.191
(.098, .285)

.04
(0, .087)
.109
(.042, .177)

0
.003
(.0, .007)

.262
(.186, .337)

.478
(.396, .561)

.18
(.103, .257)

.08
(.014, .146)

0
-

.162
(.091, .233)

.371
(.264, .478)

.291
(.197, .384)

.177
(.09, .263)

0
-

.302
(.228, .375)
.188
(.104, .272)

.395
(.325, .464)
.333
(.227, .440)

.244
(.163, .324)
.347
(247, .446)

.06
(.013, .107)
.117
(.04, .195)

0
.015
(.002, .028)

.162
(.085, .239)
298

.524
(.44, .607)
.373

.264
(.174, .354)
.175

.051
(.001, .101)
.154

0
0
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Upfront cost of
purchasing vaccine
Q3F Rural
Q3F Urban
Cost of stocking
vaccine
Q3G Rural
Q3G Urban
Lack of
reimbursement
Q3H Rural
Q3H Urban

Failure of some
insurance to pay
Q3I Rural
Q3I Urban
Time it takes to talk
about the vaccine
Q3J Rural
Q3J Urban
Difficulty ensuring
patient completes 3dose series
Q3K Rural
Q3K Urban
Not required for
school attendance
Q3L Rural
Q3L Urban

Strongly
Disagree
(.193, .402)

Somewhat
Disagree
(.262, .484)

0
.044
(0, .091)

Strongly Agree

(.11, .241)

Somewhat
Agree
(.074, .234)

.119
(.072, .166)
.035
(.018, .051)

.319
(.232, .406)
.18
(.096, .263)

.411
(.325, .497)
.601
(.492, .711)

.151
(.076, .226)
.14
(.06, .221)

0
.046
(0, .092)

.099
(.066, .132)
.036
(.0175, .054)

.279
(.201, .356)
.13
(.064, .196)

.471
(.385, .557)
.643
(.543, .744)

.151
(.071, .23)
.145
(.061, .23)

0
.043
(0, .089)

.105
(.07, .14)
.033
(.002, .064)

.318
(.228, .407)
.167
(.094, .241)

.306
(.203, .409)
.511
(.395, .626)

.271
(.17, .372)
.246
(.146, .347)

0
.035
(0, .080)

.163
(.097, .228)
.044
(.011, .078)

.330
(.251, .408)
.217
(.131, .304)

.336
(253, .42)
.467
(.354, 581)

.171
(.085, .257)
.236
(.136, .336)

0
.036
(.018, .054)

.384
(.297, .47)
.357
(.245, .469)

.426
(.35, .501)
.448
(.342, .553)

.191
(.108, .274)
.158
(.078, .237)

0
.002
(0, .004)

.020
(0, .054)

.174
(.108, .24)

.261
(.183, .339)

.524
(.424, .624)

.020
(0, .054)

.072
(.015, .130)

.260
(.154, .365)

.258
(.158, .358)

.362
(.253, .472)

.048
(0, .095)

.060
(.003, .117)
.075
(.019, .132)

.043
(.347, .512)
.205
(.121, .288)

.202
(.145, .258)
.451
(.342, .56)

.265
(.188, .341)
.201
(.129, .273)

.044
(0, .096)
.068
(.007, .129)
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Neutral

-

Table 16:
Responses to Question #4

Concern about vaccine
safety
Q4A Rural
Q4A Urban
Concern about vaccine
efficacy
Q4B Rural
Q4B Urban
Reluctance to discuss
sexuality/STI
Q4C Rural
Q4C Urban
Concern adolescent
will assume parent
condones premarital
sex
Q4D Rural
Q4D Urban
Concern adolescent
will practice riskier
sexual behavior
Q4E Rural
Q4E Urban
Lack of parental
education
Q4F Rural
Q4F Urban
Request vaccine be
deferred
Q4G Rural
Q4G Urban
Belief adolescent not at
risk
Q4H Rural
Q4H Urban

Never
0%

Rarely
1-25%

Sometimes
26-29%

Often
51-75%

Always
>75%

.011
(0, .029)
.030
(0, .081)

.359
(.277, .442)
.340
(.228, .451)

.474
(.386, .563)
.537
(.422, .652)

.135
(.06, .209)
.088
(.049, .127)

.020
(0, .054)
0
-

.052
(.009, .094)
.078
(.016, .141)

.476
(.386, .566)
.570
(.456, .684)

.400
(.323, .477)
.308
(.2, 417)

.052
(.001, .103)
.043
(.009, .078)

.020
(0, .054)
0
-

.020
(.02, .02)
.003
(0, .007)

.217
(.137, .298)
.223
(.128, .318)

.574
(.466, .682)
.457
(.353, .562)

.168
(.084, .253)
.314
(.208, .421)

.020
(0, .054)
.002
(0, .004)

0
-

.247
(.162, .332)

.692
(.598, .787)

.061
(.014, .108)

0
-

.030
(0, .08)

.341
(.232, .45)

.428
(.321, .535)

.198
(.104, 292)

.001
(0, .004)

0
-

.267
(.176, .359)

.539
(.437, .641)

.194
(.143, 245)

0
-

.035
(0, .081)

.352
(.243, .462)

.417
(.31, .524)

.196
(.111, .281)

0
-

0
-

.182
(.107, .257)

.361
(.265, .457)

.364
(.268, .461)

.092
(.031, .153)

0
-

.183
(.091, .275)

.345
(.247, .442)

.346
(.238, .454)

.126
(.048, .205)

0
0
-

.112
(.073, .15)
.161
(.071, .251)

.472
(.382, .562)
.469
(.36, .579)

.416
(.328, .504)
.331
(.24, .423)

0
.038
(0, .084)

0
0

.162
(.103, .22)
.221

.398
(.303, .492)
.348

.441
(.352, .529)
.395,

0
.037
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Parent won’t consent to
vaccine
Q4I Rural
Q4I Urban
Opposition for moral or
religious reasons
Q4J Rural
Q4J Urban

Belief adolescent is too
young
Q4K Rural
Q4K Urban
Concern about negative
media reports
Q4L Rural
Q4L Urban

Never
0%
-

Rarely
1-25%
(.123, .318)

Sometimes
26-29%
(.255, .44)

Often
51-75%
(.285, .505)

Always
>75%
(0, .083)

0
.028
(0, .073)

.374
(.246, .502)
.401
(.286, .516)

.539
(.404, .673)
.485
(.377, .594)

.087
(.015, .159)
.054
(.006, .101)

0
.033
(0, .078)

.278
(.191, .365)
.319
(.211, .426)

.479
(.385, .574)
.415
(.305, .525)

.222
(.155, .29)
.194
(.107, .28)

.020
(0, .054)
.071
(.006, .136)

0
.002
(0, .004)

0
-

.296
(.235, .356)

.581
(.493, .668)

.124
(.053, .194)

0
-

.007
(0, .018)

.182
(.089, .276)

.329
(227, .43)

.472
(.355, .589)

.009
(0, .02)

.122
(.122, .122)
.024
(0, .054)

.487
(.418, .556)
.585
(.474, .696)

.371
(.304, .437)
.371
(.259, .484)

.02
(0, .054)
.018
(.005, 030)

0
.002
(0, .004)

Research Question #2:
What knowledge do Georgia physicians enrolled in the VFC program have when
providing the HPV vaccine to their female patients?

To answer this research question, seven items assessing knowledge about HPV vaccine were
asked of the respondents. The majority of respondents answered the seven questions correctly.
Most physicians (97.2%) answered correctly that the FDA approved the quadrivalent HPV
vaccine for use in females aged 9-26 years of age. This was followed by 94.8% who knew the
FDA has approved the quadrivalent HPV vaccine for use in males for the same age group. Also
receiving a high correct response (91.1%) were those who knew almost all cervical cancers are
cause by HPV infections and 90.6% were correct that HPV causes genital warts in males and
females. The fact that HPV was a relatively common sexually transmitted disease was known
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by 86.4%. Seventy-nine point three percent of respondents were aware that females with a
diagnosis of HPV infection can still receive the HPV vaccine. The question receiving the lowest
correct score of 76.7% asked if respondents were aware that most HPV infections resolve
without medical intervention. The findings from this survey suggest knowledge of HPV and
HPV vaccine were well known by the majority of respondents.
Research Question #5:
What differences will emerge when the data are analyzed by urban vs. rural
characteristics?
To answer research question #5, Hypothesis #2 was tested.
Hypothesis #2:
No statistical differences will be detected between perceived knowledge of physicians
enrolled in VFC program who provide the HPV vaccine to females and geographic
setting (urban vs. rural).

Due to missing cells in the response categories, tests of hypothesis could not be performed.
However estimates of proportions and their standard errors were calculated and no statistical
significance was detected between perceived knowledge of physicians enrolled in VFC program
who provide the HPV vaccine to females and geographic setting. Since confidence intervals
were overlapping across response categories between urban and rural practice settings, no
statistical differences were detected.
Estimates of proportions and their standard errors to physician perceived barriers are listed
in Table 17.
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Table 17:
Responses to Question #2
Question
Most HPV infections resolve w/out medical
intervention (TRUE)
Q2A Rural
Q2A Urban

True
.818
(746, .890)

False
.067
(.010, .125)

Unsure
.114
(.069, .159)

.790
(.703, .878)

.101
(.043, .159)

108
(.036, .180)

.190
(.124, .258)

.771
(.704, .838)

.038
(0, .083)

.082
(.019, .145)

.896
(.832, .960)

.021
(.007, .036)

.881
(.822, .940)
.898
(.834, .963)

.042
(0, .091)
.065
(.009, .120)

.077
(.045, .108)
.036
(.002, .070)

Almost all cervical cancers are caused by
HPV infections (TRUE)
Q2D Rural
Q2D Urban

.874
(.805, .943)

.038
(0, . 083)

.087
(.034, .140)

.929
(.873, .986)

.039
(0, .085)

.031
(0, .064)

FDA approved HPV vaccine for use in
females age 9-26 (TRUE)
Q2E Rural
Q2E Urban

.943
(.892, .993)

.019
(0, .050)

.038
(0, .077)

.978
(.946, 1.0)

.020
(0, .052)

.001
(0, .004)

.019
0, .050)

.817
(.748, .886)

.164
(.102, .225)

.066
(.002, .128)

.776
(.679, .874)

.158
(.077, .240)

.943
(.893, .993)

0
-

.057
.007, .107

.951
(.903, 1)

.036
(0, .083)

.013,
(.002, .024)

HPV is a relatively uncommon sexually
transmitted infection (FALSE)
Q2B Rural
Q2B Urban
HPV causes genital warts in males and
females (TRUE)
Q2C Rural
Q2C Urban

Females diagnosed with HPV infection
should not be given the vaccine (FALSE)
Q2F Rural
Q2F Urban
FDA approved HPV vaccine for use in
males for permissive use for ages 9-26
(TRUE)
Q2G Rural
Q2G Urban
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Research Question #3::
What percentage of Georgia physicians enrolled in the VFC program administers the
HPV vaccine to their female patients according to Advisory Committee on
Immunization Practices (ACIP) published guidelines by providing the vaccine to their
11 – 12 year old patients?

ACIP guidelines recommend administering the vaccine to females between the ages of 1112 years of age (CDC, 2008). To answer this research question, respondents were asked if they
administered the vaccine to 11-12 year olds in their practice. Of those who responded, only
12% said they always administer the vaccine to this age group. A response of always indicated
the vaccine was given to more than 75% of female patients between the ages of 11-12 years.
Approximately 31.1% of respondents state they often administer the vaccine to this age group.
A response of often indicated the vaccine was given to 51- 75% of female patients between the
ages of 11-12 years. One quarter of respondents (24.4%) administered the vaccine sometimes to
this age group. A response of sometimes indicated the vaccine was given to 26 -50% of female
patients between the ages of 11-12 years. Respondents who rarely administer the vaccine to this
age group were 23%. A response of rarely indicated the vaccine was given to 1 - 25% of female
patients between the ages of 11-12 years. Physicians who never administer the vaccine to any
females in this age group were 8.1% indicating approximately one in ten Georgia physicians do
not administer the vaccine according to ACIP guidelines. Patterns for this analysis can be
viewed in Table 18.
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Table 18:
Administer HPV According to ACIP Guidelines
11-12 y
--------n (%)
Never (administers the vaccine to 0% of girls in this age group)

17 (8.1)

Rarely (administers the vaccine to 1-25% of girls in this age group)

48 (23.0)

Sometimes (administers the vaccine to 26 - 50% of girls in this age group)

51 (24.4)

Often (administers the vaccine to 26 - 50% of girls in this age group)

63 (30.1)

Always (administers the vaccine to 76-100% of girls in this age group)

25 (12.0)

Research Question #5:
What differences will emerge when the data are analyzed by urban vs. rural characteristics?
To answer research question #5, Hypothesis #3 was tested.
Hypothesis #3:
No statistical differences will be detected between percentage of Georgia physicians
enrolled in VFC program who indicate they recommend the HPV vaccine to male
patients, and geographic setting (urban vs. rural).

Estimates of proportions and their standard errors were calculated and no statistical
significance was detected between administering HPV vaccine to female patients according to
ACIP guidelines of administering the vaccine to 11-12 year old females and geographic setting.
Since confidence intervals were overlapping across response categories between urban and rural
practice setting, no statistical differences were detected.
Table 19 depicts estimates of proportions and their standard errors.

74

Table 19:
Administer HPV According to ACIP Guidelines with Mean and CIs
11-12 y
Urban

11-12 y
Rural

Never (administers the vaccine to 0% of
girls in this age group)

.123

.061

(.046, .2)

(.003, .119)

Rarely (administers the vaccine to 1-25%
of girls in this age group)

.246

.273

(.159, .334)

(.204, .343)

Sometimes (administers the vaccine to 2650% of girls in this age group)

.214

.175

(.133, .296)

(.113, .238)

Often (administers the vaccine to 51-75%
of girls in this age group)

.286

.354

(.182, .39)

(.219, .488)

Always (administers the vaccine to 76100% of girls in this age group)

.094

.113

(.032, .156)

(0, .225)

Research Question #4:
What percentage of Georgia physicians enrolled in the VFC program, indicate they
will recommend the HPV vaccine to their male patients?

The ACIP recommends "permissive use" of the HPV vaccine among males age 9-26 years
(MMWR, May 28, 2010). To answer this research question, respondents were asked if they
recommended the vaccine to males in their practice and if so at what age was it recommended.
Age grouping of male patients was broken down into categories of 9-10 years old, 11-12 years
old, 13-17 years old and 18 – 26 years old. Responses are listed in Table 20. Of those who
responded, only 10.9% said they always recommend the vaccine to 9-10 year old males. A
response of always indicated the vaccine was recommended to more than 75% of male patients
between the ages of 9-10 years. Respondents who often recommend the vaccine to this age
group were 10.4%. A response of often indicated the vaccine was recommended to 51- 75% of
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male patients between the ages of 9-10 years. Respondents who sometimes recommend the
vaccine to this age group were 10.9%. A response of sometimes indicated the vaccine was
recommended to 26 -50% of male patients between the ages of 9-10 years. Respondents who
rarely recommend the vaccine to this age group were 23.2%. A response of rarely indicated the
vaccine was recommended to 1 - 25% of male patients between the ages of 9-10 years.
Physicians who never recommend the vaccine to any males in this age group were 40.8%. A
response of never indicated the vaccine was not given to anyone in this age group,
Of those who responded to recommending the vaccine to 11-12 year old males, 23.7% said
they always recommend the vaccine to 11-12 year old males. A response of always indicated the
vaccine was recommended to more than 75% of male patients in this age group. Respondents
who often recommend the vaccine to this age group were 19.4%. A response of often indicated
the vaccine was recommended to 51- 75% of male patients between the ages of 9-10 years.
Respondents who sometimes recommend the vaccine to this age group were 13.7%. A response
of sometimes indicated the vaccine was recommended to 26 -50% of male patients between the
ages of 11-12 years. Respondents who rarely recommend the vaccine to this age group were
16.1%. A response of rarely indicated the vaccine was recommended to 1 - 25% of male
patients between the ages of 11-12 years. Physicians who never recommend the vaccine to any
males in this age group were 23.8%. A response of never, indicated the physician did not
vaccinate anyone in this age group, indicating approximately one fourth of Georgia physicians
do not recommend the vaccine according to ACIP guidelines to males age 11-12 years.
Of those who responded recommending the vaccine to 13-17 year old males, 26.9% said
they always recommend the vaccine to 13-17 year old males. A response of always indicated the
vaccine was recommended to more than 75% of male patients in this age group. Respondents
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who often recommend the vaccine to this age group were 20.2%. A response of often indicated
the vaccine was recommended to 51- 75% of male patients between the ages of 13-17 years.
Respondents who sometimes recommend the vaccine to this age group were 13.7%. A response
of sometimes indicated the vaccine was recommended to 26-50% of male patients between the
ages of 13-17 years. Respondents who rarely recommend the vaccine to this age group were
15.4%. A response of rarely indicated the vaccine was recommended to 1 - 25% of male
patients between the ages of 13-17 years. Physicians who never recommend the vaccine to any
males in this age group were 17.8%. A response of never indicated the physician did not
vaccinate anyone in this age group suggesting approximately one of five Georgia physicians do
not recommend the vaccine according to ACIP guidelines to 13-17 year old males. Responses
are summarized in Table 20.
Of those who responded to recommending the vaccine to 18-26 year old males, 22.4% said
they always recommend the vaccine to 18-26 year old males. A response of always indicated the
vaccine was recommended to more than 75% of male patients in this age group. Respondents
who often recommend the vaccine to this age group were 14.3%. A response of often indicated
the vaccine was recommended to 51- 75% of male patients between the ages of 13-17 years.
Respondents who sometimes recommend the vaccine to this age group were 11.9%. A response
of sometimes indicated the vaccine was recommended to 25 – 50% of male patients between the
ages of 18-26 years. Respondents who rarely recommend the vaccine to this age group were
15.7%. A response of rarely indicated the vaccine was recommended to 1 - 25% of male
patients between the ages of 18-26 years. Physicians who never recommend the vaccine to any
males in this age group were 13.8%. A response of never indicated the physician did not
vaccine anyone in this age group suggesting approximately one of five Georgia physicians do not
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recommend the vaccine according to ACIP guidelines to 18-26 year old males. Responses are
summarized in Table 20.
Table 20:
Recommend HPV to Boys by Age Group
9-10 y
--------(%)
40.8%

11-12 y
--------(%)
23.2%

13-17 y
--------(%)
17.8%

18-26 y
--------(%)
13.8%

Rarely (administers the vaccine to 25%
of boys in this age group)

23.2%

16.1%

15.4%

15.7%

Sometimes (administers the vaccine to
26-50% of boys in this age group)

10.9%

13.7%

16.3%

11.9%

Often(administers the vaccine to 51-75%
of boys in this age group)

10.4%

19.4%

20.2%

14.3%

Always (administers the vaccine to 76100% of boys in this age group)

10.9%

23.7%

26.9%

22.4%

Never (administers the vaccine to 0% of
boys in this age group)

Research Question #5:
What differences will emerge when the data are analyzed by urban vs. rural
characteristics?
To answer research question 5, Hypothesis #4 was tested.
Hypothesis #4:
No statistical differences will be detected between percentage of Georgia physicians
enrolled in VFC program who indicate they recommend the HPV vaccine to male
patients, and geographic setting (urban vs. rural).
Estimates of proportions and their standard errors were calculated and no statistical
significance was detected between recommending HPV vaccine to male patients, and geographic
setting. Since confidence intervals were overlapping across response categories between urban
and rural practice setting, no statistical differences were detected.
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Estimates of proportions and their standard errors to physician perceived barriers are listed
in Table 21
Table 21:
Recommend HPV to Boys According to ACIP Guidelines
Never

Rarely

Sometimes

Often

Always

Q8A Rural
9-10 yr old

.304
(.213, .396)

.288
(.216, .36)

.163
(.124, .203)

.081
(.03, .133)

.139
(.106, .172

Q8A Urban
9-10 yr old

.394
(.288, .501)

.118
(.045, .19)

.095
(.031, .158)

.076
(.02, .131)

Q8B Rural
11-12 yr old

.163
(.074, .253)

.225
(.129, .321)
.
118
(.072, .165)

.190
(.118, .262)

145
(.07, .22)

.360
(.278, .44)

Q8B Urban
11-12 yr old

.171
(.103, .24)

.159
(.078, .24)

.17
(.088, .253)

.221
(.124, .319)

.186
(.096, .276)

Q8C Rural
13-17 yr old

.143
(.06, .227)

.118
(.072, .165)

.159
(.094, .225)

.196
(.111, .281)

.359
(.278, .44)

Q8C Urban
13-17 yr old

126
(.066, 186).

.122
(.049, .196)

.244
(.142, .346)

.215
(.117, .313)

Q8D Rural
18-26 yr old

.090
(.015, .156)

.141
(.083, .199)

.102
(.054, .149)

.113
(.041, .185)

.2
(.108, .292)
.
265
(181, .349)

Q8D Urban
18-26 yr old

.099
(.048, .15).

.145
(.062, .228)

.178
(.095, .261)

.139
(.063, .216)

.132
(.059, .204)

After completing all descriptive statistics and reviewing all data, a combination of three new
variables were created. The three new variables are: knowscore, barriers, and parental barriers.
Knowscore measured the physician's knowledge as ascertained through question 2 on the survey.
Question 2 contained seven sub-questions and for each correct response the physician was
awarded one point. The scores range from 0 to seven.
The second new variable, barriers, measured the physician's perception of barriers as
ascertained from question 3 on the survey. For each barrier the physicians agreed with (agree or
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strongly agree) the physician was awarded one point. There are 12 listed barriers, with score
range from 0 to 12.
The third and final variable, parental barriers, measured the physician's perception of
parental barriers as ascertained from question 4 on the survey. For each parental barrier the
physicians agreed with (agree or strongly agree) the physician was awarded one point. There are
12 listed barriers, so the scores ranged from 0 to 12.
As each of these three new variables represents a new summative scale, Cronbach's alpha
was calculated to assess the reliability of scales. For the Knowscore scale consisting of seven
items, Cronbach's Alpha = 0.744, which can be consisted moderately good. For the Barrier Scale
with 12 items, Cronbach's Alpha = 0.808, again, a moderately good reliability. Finally, for the
Parental Barrier Scale, consisting of 12 items, Cronbach's Alpha = 0.822, and provides
moderately good reliability.
Since the three new variables were created, summary statistics that incorporate the sample
design (calculated with SAS Proc Surveymeans) are illustrated in Table 22.
Table 22:
Summary Statistics Across Counties
Variable

Mean(SE)

Lower 95% limit

Upper 95% limit

Barrier

4.18(0.25)

3.76

4.60

Parental Barrier

2.47(0.24)

2.06

2.88

Knowscore

6.16(0.10)

5.98

6.33

Since the three new variables were created, summary statistics that incorporate the sample
design (calculated with SAS Proc Surveymeans) are given in Table 23.
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Table 23:
Summary Statistics Rural and Urban
Variable

Mean(SE)

Lower 95% limit

Upper 95% limit

Barrier

3.77 (0.48)

2.98

4.61

Parental Barrier

2.42 (0.49)

1.58

3.23

Knowscore

6.16 (0.25)

5.73

6.59

Barrier

4.33 (0.28)

3.85

4.81

Parental Barrier

2.49 (0.27)

2.02

2.96

Knowscore

6.16 (0.10)

5.98

6.34

Rural

Urban

After summary statistics incorporating the sample design were established, logistic
regression analysis was performed to determine variables that may influence a physician's
decision to not recommend the HPV vaccine to their patients. There were two dependent
variables of interest: females’ age 11-12 years and males age 11-12 years. Table 24 refers to
females not getting an HPV vaccine recommendation.
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Table 24:
Females Age 11-12 Not Getting HPV Vaccine Recommendation
Effect

Df

Wald statistic

P-value

%Medicaid

4

191.63

<0.001***

Physician gender

1

3.946

0.047***

Knowscore

1

0.216

0.641

Barrier

1

0.057

0.812

Parental barrier

1

6.721

<0.001***

% Medicaid is most likely a spurious result due to only 2 providers not accepting Medicaid.

The significant effect (p < 0.001) detected by having Medicaid as a payer sources is most
likely a spurious result due to only two providers not accepting Medicaid. A significant effect
(p=0.047) was detected between physician gender and a female patient not getting a
recommendation for HPV vaccine. A second significant effect (p<0.001) was detected between
parental barrier and a female not getting an HPV vaccine recommendation.
Next, confidence limits on odds ratio was performed to further determine variables that may
influence a physician's decision to not recommend HPV vaccine to their patients. Refer to Table
25 for estimated odds ratio and 95% confidence intervals.
Table 25:
Confidence Limits on Odds Ratios for Not Getting HPV Recommendation
Effect

Estimated OR

95% C.I. for Odds Ratio

Medicaid 1 vs. 5 (0% vs. 76-100%)

<0.001

(<0.001, <0.001) ***$$$

Medicaid 2 vs. 5 (1-25% vs. 76-100%)

3.762

(0.268, 52.709) NS
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Effect

Estimated OR

95% C.I. for Odds Ratio

Medicaid 3 vs. 5 (26-50% vs. 76-100%)

2.960

(0.772, 11.347) NS

Medicaid 4 vs. 5 (51-75% vs. 76%-100%)

1.439

(0.315, 6.573) NS

Gender (female vs. male)

3.071

(1.015, 9.293) ***

Knowscore

0.895

(0.562, 1.427) NS

Parental Barrier

0.986

(0.881, 1.104) NS

Barrier

1.154

(1.035, 1.285) ***

*** indicates statistical significance at alpha=0.05, $$$- spurious result (there are only 2 providers for less than 1%
who state 0% Medicaid)

Parental barrier was significant with an estimated odds ratio of 1.154. Of interest was the
estimated odds ratio for female physicians to not recommend the HPV vaccine to their female
patients of 3.071 indicating physician gender has an impact on the likelihood of vaccination.
Other variables were not considered significant.
The likelihood of physicians to not recommend the HPV vaccine to males’ ages 11-12 years
was explored. Logistic regression analysis was performed to determine variables that may
influence a physician's decision to not recommend HPV vaccine to their male patients as shown
in Table 26 for estimated odds ratio and 95% confidence intervals.
Table 26:
Males 11-12 Years Not Getting HPV Recommendation
Effect

Df

Wald statistic

P-value

%Medicaid

4

3.545

0.471

Physician gender

1

3.171

0.075

Knowscore

1

2.394

0.122

Barrier

1

0.156

0.693
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Effect

Df

Wald statistic

P-value

Parental barrier

1

2.592

0.108

No significant effect (p < 0.05) was detected with any variable. Confidence limits on odds
ratio was performed to further determine variables that may influence a physician's decision to
not recommend HPV vaccine to their male patients. No significant effects were detected. Refer
to Table 27.
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Table 27:
Confidence Limits on Odds Ratios for Not Getting HPV Recommendation

Effect

Estimated OR

95% C.I. for Odds Ratio

Medicaid 1 vs. 5 (0% vs. 76-100%

0.791

(0.173, 3.624) NS

Medicaid 2 vs. 5 (1-25% vs. 76100%)

2.780

(0.218, 35.459) NS

Medicaid 3 vs. 5 (26-50% vs. 76100%)

1.022

(0.256, 4.082) NS

Medicaid 4 vs. 5 (51-75% vs. 76%100%)

0.740

(0.175, 3.121) NS

Gender (female vs. male)

2.529

(0.911, 7.021) NS

Knowscore

0.662

(0.392, 1.116) NS

Parental Barrier

1.039

(0.860, 1.256) NS

Barrier

1.132

(0.973, 1.317) NS

*** indicates statistical significance at alpha=0.05.
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Chapter 5
SUMMARY, DISCUSSION, AND CONCLUSIONS
The purpose of this study was to examine the prevalence of Georgia physician intention and
administration of HPV vaccine to 11-12 year-old girls and intention to recommend the
quadrivalent HPV vaccine to 11-12 year old boys. The study examined the attitudes and beliefs
of Georgia physicians toward administering HPV vaccine and assessed perceived knowledge,
barriers, practices, and adherence to ACIP guidelines and recommendations regarding HPV
vaccination. A distinction between urban and rural counties was examined to determine if there
were differences.
Summary of Findings
The response rate for this study was 82.6%, with physicians and key informants representing
Georgia physicians in the VFC program who administer HPV vaccine to their male and female
patients. The diverse representation of the respondents included 51.4% White, 22.6% Asian and
18.4% African American. Latino’s were noted to be 9.5% of respondents. Males accounted for
51% and females were 49% of respondents. Respondents practicing in rural counties represented
18.8% and urban county respondents were 81.2%. Practice size ranged from single physician
practices to one practice with more than 26 physician providers.
Research Question #1: Descriptive analysis of data showed 64.2% believed the most
important barrier for not vaccinating was lack of adequate reimbursement for HPV vaccination.
The barrier of inadequate reimbursement was followed by 63.2% citing the cost of stocking the
HPV vaccine and 60.8% believing the upfront or initial cost of purchasing the private stock HPV
vaccine was a barrier. Only 9.9% had concerns about the safety of the HPV vaccine. Many
physicians commented on the lack of reimbursement by private insurance companies. Research
86

by Kahn et al. (2009) with Texas physicians yielded nearly identical findings as it pertains to
barriers of cost and reimbursement. In the Texas study, 67.1% noted lack of payment by some
insurance companies as a barrier compared with 64.2% in this research (Kahn et al., 2009). This
is especially important for those physicians with practices that do not contain many VFC patients
where cost of the vaccine is covered. Gudeman (2007) had similar findings and observed that
while VFC programs work for those who qualify; those who do not qualify for the VFC program
do not benefit from vaccination and reimbursement remains an issue. As one physician noted:
“I would give more vaccine if insurance paid for it. It is difficult to ask a mother
to pay $350.00 for a vaccine not required for school and not covered by her
insurance.”

The most significant parental barrier to vaccination according to Georgia physicians was the
request that HPV vaccine be deferred until the female patient was older. This barrier was noted
by 89.9% of respondents followed by lack of education/understanding of the HPV vaccine at
83.2%. Parental opposition to HPV vaccination for moral or religious reasons was a barrier to
less than one in four physicians. Previous research (Charo, 2007; Daley et al., 2006; Katz et al.,
2009; Tissot et al., 2007) suggested strong religious beliefs lead to a delay or refusal of vaccine
was not found in this research. One Georgia physician summed what others stated by observing:
“I have never had a mother tell me it was against her religious belief to not
vaccinate with this vaccine. I think the press made a big deal in the beginning
when the vaccine was new, but it is not true.”

Research Question #2: The overall knowledge about HPV and who could receive the HPV
vaccine was well known by most respondents. Over 90% of respondents were aware that the
FDA approved the quadrivalent HPV vaccine for males and females, that almost all cervical
cancers are caused by HPV, and that HPV also causes genital warts in both sexes. The
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remaining survey questions were answered correctly by over 75% of respondents and pertained
to knowledge that HPV is a sexually transmitted disease which usually resolves without medical
intervention and that females with an HPV may still receive the vaccine. These combined scores
indicate an overall high rate of knowledge among respondents. These findings of Georgia
physicians are similar to finding by Daley et al. (2010) in a national survey of physician
knowledge.
Research Question #3: Vaccinating females according to ACIP guidelines at age 11-12
years was performed by 12% who stated they always administer the vaccine to this age group.
Many providers who administer the vaccine stated they use reminders to assist with vaccination
and use a positive, professional approach:
“I tell the mom I am going to vaccinate at the next visit, then at that visit I have a
matter of fact approach about it, no big deal, I vaccinate and talk about how this
vaccine protects against cervical cancer and that I wish there were more
vaccines that protected against other types of cancer. I tell the mother there are
two more shots and that my office will remind her when to bring her daughter
back.”

Other physicians were less compliant when vaccinating 11-12 year old females. Indeed,
30.1% stated they were successful with 51-75% of their patients, and about one-quarter of
respondents was successful with 26 – 50% of their female patients in this age group. Multiple
physicians stated parental concern about the age of the child as a barrier, noting:
“I recommend the vaccine beginning at age 10 but moms have different reasons
why they want to wait to have their daughters vaccinated. Some wait until their
daughter goes to high school in case she talks about it with her friends and I’ve
had some moms that wait until their daughter start their menstrual cycle. If
insurance does not cover it, moms will often refuse the vaccine.”
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Physicians who never vaccinate females at 11-12 years of age were 8.1%. One physician
summed what others who did not vaccinate at this age noted:
“Most women wait until their daughter is at least 13 years old and then they
bring her in for the vaccine. It is less of a concern to the mom at that age.”
These findings of Georgia physicians are similar to finding by Daley et al. (2010) in a
national survey of physician vaccination. Other researchers (Kahn et al., 2008; Katz et al., 200;
Ko et al., 2010 & Shan et al., 2007) has similar findings indicating physicians appear to be
delaying vaccinating until the adolescent is past of age of 12 and not vaccinating according to
ACIP guidelines.
Research Question #4: Analysis of the data revealed less than one-quarter of physicians
always recommend the HPV vaccine to male patients at any age. The fewest physicians
recommend it to males 9-10 years with only 10.9% recommending. In addition, the physicians
who stated they never recommended the vaccine was surprising with 40.8% stating they never
recommend HPV vaccination to 9-10 year olds. The data were slightly better for 11-12 year old
males with 23.7% stating they always recommend the vaccine and 23.2 % stating they never
recommend the vaccine to 11 -12 year old males. Other researchers (Weiss et al., 2010) who
studied physicians currently administering HPV vaccine to females suggest physicians supported
the concept of vaccinating males for the benefits it imparts on both sexes. Recommending the
vaccine early and to both sexes was seen as important. By doing so, patient and parent can be
educated about the HPV vaccine and vaccination may occur at the next annual visit. As one
physician commented:
“It is difficult enough to get girls vaccinated, I am just now starting with the
boys. I tell them I think they should have it but they don’t see it as important or
something they need right now.”
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Research Question #5: No difference emerged when the data were analyzed by urban or
rural geographic location. This may be attributed to sample size but the response rate for this
study was 82.6%. Data reveals that geographic location of physician practice does not appear to
impact HPV vaccine administration.
After completing analysis for the research questions with no significant findings, three new
variables were created to reveal what may cause physicians not to recommend HPV vaccination.
From these three new variables, logistic regression was used to determine that female physicians
and parental barriers made it more likely that female patients 11-12 years of age would not
receive a recommendation for HPV vaccination. There was no effect on not recommending the
HPV vaccine to male patient’s age 11-12 years.
The findings that method of payment, such as having a low percentage of patients with
Medicaid as a payer source, appears to be a spurious result because less than 1% of respondents
were in this category.
To summarize the findings, none of the original variables (administering the HPV vaccine to
11-12 year old females according to ACIP guidelines, recommending the HPV vaccine to males,
barriers, or knowledge) impacted differences among urban and rural physician providers in
Georgia although female physicians and parental barriers appear to be make it more likely that
11-12 year of female patients will not receive a recommendation for vaccination.
Health Belief Model and Research Findings
HPV vaccination by physicians within the framework of the Health Belief Model was used
to inform this research. The Health Belief Model views key determinants of health and illness to
be individual health behavior (Becker, 1974; Glanz, et al., 2008; Rosenstock, 1974). Using the
Health Belief Model, perceived susceptibility manifested by physician knowledge that patients
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are at risk for HPV infection was evident by the correct responses to the survey. Physicians
correctly answered survey questions pertaining to HPV infection and the immense prevalence of
the virus within the population.
Perceived susceptibility
As previously noted by Brown (2005), the cumulative prevalence of HPV infection in
sexually active adolescent females is high, and physicians must educate parents and adolescents
about the risks if improved vaccination rates are to be achieved. Physician education of parents
can increase the parent’s understanding of adolescent susceptibility. The knowledge could lead
to increased HPV vaccination. This is vital because 80.8% of respondents to this survey
indicated parents do not believe their adolescent to be at risk for HPV. These finding suggests
low perceived susceptibility to the human papillomavirus when in fact over 70% of sexually
active men and women will acquire a genital HPV infection during their lifetime (CDC 2010).
Perceived severity
Perceived severity of HPV infection leading to problems of genital warts and possible cervical
cancer were known by the majority of physicians in this survey. Most HPV infections are
asymptomatic, transient, and resolve without medical intervention (CDC 2010). Most physicians
were aware of this fact as was noted in this research and studies by Daley et al. (2010) and Kahn
et al. (2009). These studies also showed a high adoption rate of vaccination by physicians with
most physicians aware of several key aspects of HPV epidemiology. While not all adolescents
will go on to have genital warts or develop cervical cancer, submitting accurate information to
physicians will allow them to make informed decisions about vaccination and could prevent
many future cases.
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Perceived benefits
Keeping within the framework of the Health Belief Model, perceived benefits of vaccinating
which reduces the risk of HPV infections was known by most respondents in this survey.
Nevertheless, for the benefits of vaccination to be realized, the vaccine must be administered
before the onset of sexual activity and exposure to HPV virus (Markowitz et al., 2007) if it is to
be most effective. Research by Daley et al. (2010) note physicians are well aware of HPV and
HPV vaccine but at least 25% of physicians in that study do not follow ACIP guidelines of
vaccinating 11-12 year olds and often wait until after 13 years of age. Their findings were
similar to findings in this research of Georgia physicians which noted 8.1% never vaccinate and
23% rarely vaccinate 11-12 year olds.
When placed in the framework of the Health Belief Model, there are opportunities to
increase HPV vaccination rates of this age group. For example, school entry laws create a
perceived benefit of vaccination, yet HPV vaccination is not mandated in Georgia or most other
states (Charo, 2007). Currently in Georgia, students must receive or show proof of having
tetanus, diphtheria, pertussis, hepatitis B, polio, measles, mumps, rubella and varicella
vaccinations or have a religious exemption before attending school (Georgia Department of
Education, 2010). This is not the case for HPV vaccine. By mandating HPV vaccine for middle
school entry, a perceived benefit is implied, particularly if physicians support the school
mandate. However, the American Academy of Family Physicians note in their 2007 policy
statement that they would recommend the vaccine as a mandate for school admission only after
“long term safety with widespread use, stability of supply, and economic issues have been
clarified” (AAFP 2007). The position of the AAFP has not changed and there is still no
recommendation to include HPV vaccine as part of school mandated vaccines (AAFP, 2011).
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In one survey by Horn, Howard, Waller, and Ferris, (2010), most parents supported
mandatory vaccination programs in general, but less than half who responded to the survey felt
the HPV vaccine should be mandated. The main reasons for nonsupport were that it would
infringe on their rights, that the vaccine had not been well studied, and had too many adverse
effects.
Perceived barriers
Within the framework of the Health Belief Model, barriers identified by this research are
viewed as components that converge to yield the final decision to vaccinate or not to vaccinate.
For example, cost of the vaccine was cited as just one barrier by many physicians who took part
in this research. Brewer and Fazeka (2007) noted variables associated with HPV vaccine
initiation in multivariate analyses included the barrier of the physician’s ability to store HPV
vaccine and perceived barriers to obtaining HPV vaccine.
For parents, cost of missed working hours and transportation costs must also be considered.
Many adolescents do not have private health insurance that covers the cost of the vaccine. Those
that may be eligible may not take advantage of public programs such as Medicaid or VFC.
Another barrier within the framework of the Health Belief Model is under-utilization of
health care services by male and female adolescents. If HPV vaccine education is to occur
during the physician visit, then the visit must first occur. Then the physician can impart his
beliefs regarding perceived susceptibility and severity of disease, and perceived benefits of
vaccination. The AMA (2011) recommends three visits from age 11 -21 years. The first visit is
recommended between the ages of 11-14, one visit for ages 15-17 and the last visit before the
21st birthday. Within the framework of the Health Belief Model, if the physician perceives the
severity of HPV and the adolescent’s lifetime susceptibility of the disease, and if the physician
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has the self-efficacy to administer the vaccine, then the physician will use this visit as a cue to
action to recommend and administer the vaccine provided the adolescent makes the visit.
Cues to action to vaccinate and self-efficacy
Cues to action to vaccinate and self-efficacy were not explored in depth in this research but
should be the subject of future research. McCave (2010) noted vaccination rates improved when
the physician had a personal belief in the positive impact of the HPV vaccine and office
strategies which supported vaccination. Effective physician strategies for HPV vaccine delivery
(Tissot, et al., 2007) indicated multiple office approaches improved vaccination rates.
Implementing office-based procedures and policies, providing education and information
opportunities to physicians and parents, and ensuring endorsement of HPV vaccination by
influential organizations, were noted to be effective.
Although the main purpose of this research was to provide a quantitative assessment of
Georgia physician intention and administration of the HPV vaccine to 11-12 year-old girls and
intention to recommend the HPV vaccine to 11-12 year old boys, a rich compilation of
qualitative information accompanies the data set. This will provide the basis for future analysis
and reporting and further contribute to the knowledge base in this area of public health.
Discussion of Findings
Despite national recommendations for universal vaccination of 11-12 year old females,
approximately one in ten Georgia physicians (12%) who responded to this survey reported they
always vaccinate females in this age group. The number increases to one in five (22.9%) who
reported they always vaccinate females age 13-17 years, suggesting parents or physicians may
be delaying vaccination until females are older than 12 years. This study was conducted five
years after the ACIP recommendation to vaccinate females at 11-12 years (Markowitz et al.,
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2007) suggesting additional efforts are needed to improve physician awareness of and adherence
to national recommendations.
This study found 50.5% of Georgia physicians always recommended HPV vaccine to 11-12
year old females which was similar to the findings of a Texas study (Kahn et al., 2009) where
48.5% reported they always recommend HPV vaccination at this age. A national internet and
standard mail survey of physicians by Daley et al. (2010) also indicated 56% of physicians
strongly recommend the vaccine to this age group. As the girls become older, this study
indicated 69.9% always recommend the vaccine to 13-17 year olds which is very similar to
Texas physicians (Kahn et al., 2009) where 64.4% always recommend. However the national
study by Daley et al. (2010) had a higher recommendation rate of 82%.
These findings suggest more physicians strongly recommended HPV vaccination to patients
13 years and older and was the finding in this research of Georgia physicians. Research by
Daley et al. (2010) to a national group of pediatricians and family practice physicians indicated
fewer respondents strongly recommended HPV vaccination for 11-to 12-year old girls than for
older female patients. Among pediatricians, 57% said they recommended the vaccine for that age
group, but 90% recommended the vaccine for their 13- to 15-year old patients. Findings from
the national study were similar to findings of Georgia physicians from this research.
Perceived barriers to HPV vaccination indicated financial barriers and parent opposition as
reasons for not vaccinating. Financial constraints were found to be a barrier in this research by
the majority of physicians. This was also found to be a barrier in research by Kahn et al (2009)
statewide survey of Texas physicians, research by Daley et al. (2010), in a national survey of
physicians. The national survey of physicians found that vaccine costs and insurance coverage
were the main financial barriers to strongly recommending HPV vaccination.
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More than half (59.4%) Georgia physicians reported insufficient insurance coverage for the
vaccine as a barrier to their practice when offering the vaccine. HPV vaccination coverage by
both public and private health care plans remains an important issue if Georgia vaccination rates
are to increase. Physicians had experienced parental barriers to HPV vaccination, and most of
these had been anticipated by physicians in studies conducted before HPV vaccine licensing
(Daley et al., 2006; Dempsey & Davis, 2006). Findings suggest that providing physicians with
information about HPV vaccines and with strategies to educate parents while addressing specific
parental concerns will be important in overcoming barriers. State and local immunization
coalitions that focus on regaining public trust in vaccines and that encourage accurate and
responsible journalism will be essential in efforts to increase HPV vaccination rates.
The physician perceived parental barrier that the vaccinated child would practice riskier
sexual behavior was noted by 69.7% in this research. However, research published in the
American Society for Colposcopy and Cervical Pathology had a different finding and noted
“most parents do not think the HPV vaccine would actually encourage sexual activity in their
children” (Ferris, Cromwell, Waller, & Horn, 2010, p. 179). In their study, most parents thought
the HPV vaccine would not alter their children’s reproductive behavior. Their research indicated
only a very small minority of parents believed it might lead to riskier sexual behavior. Older
parents and parents with older adolescents were the ones more likely to think that HPV vaccine
encourages riskier sexual behavior. In addition, parents with a greater number of daughters were
concerned about risky sexual behavior. Their study found that these children became sexually
active shortly after receiving the vaccine by coincidence, and as a result, the vaccine was blamed
for this action. However, research by Daley et al. (2010) indicated parental concern about HPV
vaccination was also a barrier; with 39% of pediatricians and 43% of family physicians reporting
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that parents worried that vaccination against a sexually transmitted infection may encourage
earlier or riskier sexual behavior. The survey also found that 22% of pediatricians and 23% of
family physicians reported that parents of their 11- to 12-year-old patients were upset that they
were offering the vaccine to that age group. Eighteen percent of pediatricians and 29% of family
physicians reported that at least one fourth of parents of 11- to 12-year-old patients refused HPV
vaccine (P < .01). Common reasons for parent refusals were that the vaccine was too new, the
child was too young, and lack of health insurance for HPV vaccination.
Georgia physician’s attitudes about vaccinating males indicate approximately one quarter
Georgia physicians always recommend HPV vaccine to male patients. However, findings were
different when compared to recommendations for vaccinating males, with 42% of Texas
physicians (Kahn et al., 2009) indicating they were extremely likely to recommend the vaccine to
11-12 year old males.
Most physicians stated lack of payment as a barrier to vaccinating males. While the number
of physicians who always recommend the vaccine is less than those who always vaccinate
female patients, physicians may be more likely to recommend HPV vaccine as more information
becomes available about HPV related diseases in men. Nevertheless, male HPV vaccination
raises unique issues and specific educational messages for physicians, parents, and males will
need to be developed if vaccination rates are to increase.
In Georgia, female physicians and parental barriers are factors associated with not
recommending the HPV vaccine to 11-12 year old females. In a national study by Daley (2006)
surveying pediatrician’s knowledge and attitudes regarding HPV vaccination, 97% of female
pediatricians versus 81% of male pediatricians reported feeling comfortable discussing sexuality
with female patients. In a follow up study by Daley et al. (2010) female family physicians were
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more likely to give the vaccine than male family physicians. Ko et al (2010) findings suggested
female, primary care, and community and private practice physicians were associated with
increased vaccination. Physicians who took part in this research also noted the greatest barrier to
vaccination was reimbursement concerns. Reimbursement was also a barrier for Georgia
physicians.
Study Strengths and Limitations
This study provides researchers and immunization professionals with a comprehensive
examination of the prevalence of Georgia physician intention and administration of HPV vaccine
to 11-12 year-old girls, and their intention to recommend HPV vaccine to 11-12 year old boys.
The study examined the attitudes and beliefs of Georgia physicians toward administering HPV
vaccine and assessed perceived knowledge, barriers, practices, and adherence to ACIP guidelines
and recommendations regarding HPV vaccination.
The major strength of the study is its response rate of 82.6% from the sampling plan (n=264)
of Georgia physicians who administer the HPV vaccine. The researcher drew the sample from a
database maintained by the Immunization Section of the Division of Public Health within the
Department of Community Health and the database is updated annually. A second strength of
the study was the survey tool itself. We adopted a previously validated survey tool developed by
researchers from the Moffitt Cancer Center and tested by Vadaparampil (2009) from a
nationwide survey.
A limitation to this study is the possible difference in physician response in larger practices
from those who were smaller practices or practiced alone. For example, in an office practice
with two or more physicians, only one physician was asked to complete the survey. It is not
known if asking all physicians in a practice would yield the same results as asking one physician
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and this could be the basis for further research. However, researchers of physician surveys
suggest bias may be of less concern in physician surveys than in surveys of the general public
and physicians tend to be fairly homogeneous with respect to knowledge, training, attitudes, and
behaviors (Kellerman & Herold, 2001). It is also possible that some survey respondents, while
authorized by the physician to respond, might not have been the correct key informant with
appropriate knowledge and could have reported inaccurate responses. The database obtained by
the Immunization Section of the Division of Public Health within the Department of Community
Health may not have included all physicians who are on the VFC list and who administer the
HPV vaccine. Lastly, the study assessed physician-reported behavior but did not observe actual
vaccination practices.
Implication for Public Health Programs, Policies, and Allocation of Resources
In Georgia, most childhood immunizations (81%) are administered in the private sector at
physician offices (Georgia Department of Community Health, 2010). Public health must have a
firm understanding of who is recommending and administering vaccines in order to target
messages and action. As the Mission and Vision of the Immunization Section of the Georgia
Division of Public Health is to “… work to increase immunization rates for all Georgians and
decrease the incidence of vaccine-preventable diseases” (DCH, 2010), it is important to have
information about the attitudes and beliefs of Georgia physicians toward administering the HPV
vaccine and assess perceived knowledge, barriers, practices, and adherence to ACIP guidelines
and recommendations. Future efforts may focus on female gender of physician and parental
barriers with regards to recommendation of the vaccine to 11-12 year old girls, to guide
strategies.
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The Immunization Section of the Georgia Division of Public Health will be informed of
findings to assist with future immunization program outreach. As noted by Daley et al. (2010)
physicians appear more likely to recommend the HPV vaccine at older ages and vaccination may
not occur at the age recommended by national guidelines. Therefore, educational materials
should highlight ACIP guidelines and recommendations of HPV vaccination. The finding that
financial barriers exist will assist the Immunization Section target the release of VFC vaccine
and information to areas where providers may have experienced difficulty in vaccinating
uninsured and under-insured children. The finding of female physicians being less likely to
recommend the HPV vaccine to 11-12 year old female patients will be shared with local medical
organizations to determine best approaches for addressing this finding and encouraging
vaccination.
According to Healthy People 2010 (USDHHS, 2000), programs that employ social
ecological model approaches for immunization are becoming more prevalent, with policy
intervention at the societal level being one strategy to impact change. Policy that includes the
option of creating a state mandate in Georgia would improve overall HPV vaccination rates
among the target population. However, it is not certain that physicians and other key
stakeholders are prepared to endorse a state mandate in Georgia.
Engaging physicians in the policy debate of a future state mandate will be necessary if
higher rates of HPV vaccine uptake among the population are to be realized and if policy is to
change. Although only 15.1% of physicians surveyed believed not requiring a school mandate to
be a barrier, the fact remains that overall vaccination rates according to ACIP guidelines is 38%
in Georgia (MMWR 2010).
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This study provides the first comprehensive examination of the prevalence of Georgia
physician intention and administration of the HPV vaccine to 11-12 year-old girls, and their
intention to recommend the HPV vaccine to 11-12 year old boys. While the findings are similar
to other studies completed nationally and in different states, this is the first such study to be
conducted in Georgia. As such, its contribution to Georgia’s public health’s promoting
comprehensive adolescent immunization is important. It serves as a snapshot of what is
happening in Georgia and as baseline data for future studies.
The Office of Immunization within the Georgia Division of Public Health will be able to
use data from this and future studies to create a baseline for vaccine outreach, marketing
campaigns, grant activities, and legislative education. Having baseline immunization data can be
the first step in creating policy that targets those who provide the majority of immunization. It
can only do this by engaging the physicians who administer the most vaccine. Having a better
understanding of physician knowledge, attitude and vaccination practice is the first of many steps
toward improved immunization rates. By sharing and following examples of others, physicians
can customize messages and parent education to better meet the needs of their distinctive patient
population. As one physician noted:
“I have no idea what others do (in their office), I could be leading the pack or
bringing up the rear.”

Public health practitioners should strive to increase the number and percentage of males and
females who receive HPV vaccine to comply with ACIP guidelines and to promote overall health
and wellness among the population. One local activity “Tea and HPV” that appears to have met
with moderate success will be shared across the state and may also prove useful in other states to
increase HPV vaccination rates. “Tea and HPV” utilized the school setting as a place to bring
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young girls together with their mothers to learn more about the virus and vaccine. The middle
school was opened after school hours to female students in the fifth and six grade and their
mothers. The lunchroom was decorated and parents were served light refreshments by their
daughters. Public Health nurses provided a brief presentation on HPV and remained to answer
any questions. A similar venue can be done with boys and their fathers.
Suggestions for Future Research
Although the main purpose of the current study was to provide a quantitative assessment of
Georgia physician intention and administration of the HPV vaccine to 11-12 year-old girls and
their intention to recommend the HPV vaccine to 11-12 year old boys, a rich compilation of
qualitative information accompanies the data set. Future efforts may focus on female gender of
the physician and parental barriers with regards to recommendation of the vaccine to 11-12 year
old girls, to guide strategies. Focus groups of female physicians with public health professionals
facilitating may lead to an expansion of reasons given for not recommending the vaccine. This
will be beneficial if efforts to increase rates are to be realized in Georgia. It may also be useful
to include parents in separate focus groups to allow them freedom to express their concerns and
barriers to vaccinating their younger daughters. Efforts to explore barriers of physicians and
parents may lead to modifications in social media and actions that could be applied to other
states.
Other areas of focus for researchers may include examining how the HPV vaccine is
supplied to determine if providing the vaccine in smaller unit packages has an impact on the
physician barrier of cost of stocking the vaccine. Finally, another focus may be exploring how
public health communicates vaccine information and education to physician offices. While
92.5% of respondents indicated they received vaccine information from state and location
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immunizations programs, a knowledge gap remains. Educating the physician about the VFC
program and which patients may qualify for this program is another area for future research.
Most physicians in this study indicated financial barriers kept them from recommending and
administering the HPV vaccine more often to their patients. The VFC program is available to
reimburse the physician for providing the vaccine to children who do not have insurance or who
have insurance that does not cover the cost of HPV vaccine. As all physicians in this study were
VFC providers and may not be aware of how this program could help their patients who do not
have insurance. Further research to explain why physicians are not utilizing this program to
cover the cost of vaccine for their uninsured and underinsured patients, should be explored. The
VFC program is a federal program and findings may be applicable to other states.
The current practice in the Georgia Immunization Sections is to provide new vaccine
information and communications through telephone fax and email to the physician office.
However, it is not known if all physician locations receive this information or if the telephone
fax or email address is current. Indeed, when physicians change office location, retire, or move
to another practice, this information may not be available to the Georgia Immunization Section.
In this case, current information on vaccine changes will not be known to the physician. An
annual review of the VFC provider list to verify telephone fax and email information is
necessary to ensure all physicians have access to the most current vaccine information and can
apply the information at their practice.
Conclusion
This study was intended to provide an assessment of HPV vaccination by Georgia
physicians to assess perceived knowledge, barriers, supports, practices, and adherence to ACIP
guidelines and recommendations. A proportionate stratified random selection method was
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utilized to survey pediatricians, family physicians, gynecologists, and internal medicine
physicians in Georgia. The final sampling frame included 264 (n=264) physicians who
administered the HPV vaccine, 62 in rural counties and 202 in six urban counties. Response rate
to the survey was 82.6% yielding a high degree of reliability.
As a result of this study, 64.2% believed the most important barrier for not vaccinating their
female patients was lack of adequate reimbursement. The most significant parental barrier to
vaccination according to 89.9% was the request that HPV vaccine be deferred until the female
patient was older, confirming female adolescents ages 13 to 17 are getting vaccinated in higher
proportions than their pre-adolescent counterparts.
Knowledge about HPV and who could receive the vaccine was correctly known by >90% of
respondents. Vaccinating females according to ACIP guidelines at age 11-12 years was
performed consistently by only 12% of respondents. Less than one quarter of physicians
consistently recommend HPV vaccine to male patients at 11-12 years of age.
No difference emerged when the data were analyzed by urban or rural geographic location.
Three new variables created revealed through logistic regression that female physicians and
parental barriers made it more likely that female patients 11-12 years of age would not receive a
recommendation for HPV vaccination.
This study adds to existing research highlighting the importance of considering barriers and
supports, particularly the influence of financial barriers. It also points to the significance of
personal beliefs, specifically having a belief that the HPV vaccine will have a positive impact on
young men and women’s lives. Future efforts may focus on female gender of the physician and
parental barriers with regards to recommendation of the vaccine. Scholars from public health
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will be at the research table and join others as part of the creation of a new body of literature with
state-wide implications.
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methodology becomes necessary, you must notify the IRB Coordinator prior to initiating any such changes or
modifications. At that time, an amended application for IRB approval may be submitted. Upon completion of your
data collection, you are required to complete a Research Study Termination form to notify the IRB Coordinator, so
your file may be closed.
Sincerely,
Eleanor Haynes
Eleanor Haynes
Compliance Officer
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C. Sampling Frame

Selection method: PPS without replacement – Original Sampling Frame

County
Obs type
County name
Rural
Wilkinson
County
1

Pop 2000

Pop 2009

Public Health District

Number
prov

Selection
Prob

Sampling Weight

10220

10076 5-2 North Central
(Macon)

1

0.04255

23.5000

17044 8-1 Valdosta

2

0.08511

11.7500

2

0.08511

11.7500

2 Rural

Berrien County

16235

3 Rural

Hancock
County

10074

4 Rural

Jeff Davis
County

12685

13659 9-2 Waycross

2

0.08511

11.7500

5 Rural

Mitchell
County

23934

23800 8 -2 Southwest

4

0.17021

5.8750

6 Rural

Franklin
County

20287

21748 2 North (Gainesville)

5

0.21277

4.7000

7 Rural

Appling
County

17419

18011 9-2 Waycross

6

0.25532

3.9167

8 Rural

Jefferson
County

17263

16478 6 East Central (Augusta)

6

0.25532

3.9167

9 Rural

Lumpkin
County

20979

27528 2 North (Gainesville)

6

0.25532

3.9167

10 Rural

Toombs
County

26067

27959 9-2 Waycross

6

0.25532

3.9167

11 Rural

Wayne County

26565

29407 9-2 Waycross

6

0.25532

3.9167

12 Rural

Sumter County

33200

32084 7 West Central

11

0.46809

2.1364

13 Urban

Spalding
County

58417

64708 4 LaGrange

7

0.04110

24.3333

14 Urban

Gordon County

44104

53292 1-1 Rome

10

0.05871

17.0333

15 Urban

Houston
County

110765

135715 5-2 North Central
(Macon)

11

0.06458

15.4848

16 Urban

Clayton
County

236520

275772 3- 3

33

0.19374

5.1616

17 Urban

Fulton County

815827

113

0.66341

1.5074

18 Urban

Gwinnett
County

588450

118

0.69276

1.4435

9219 5-2 North Central
(Macon)

1033756 3-2 Fulton
808167 3 – 4 Gwinnett
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D HPV Survey of Physicians
HPV Survey
The survey is an assessment of HPV vaccination knowledge, barriers, and practice guidelines. Questions
are designed to match up with the most current guidelines and recommendations published by the Advisory
Committee on Immunization Practice (ACIP). The answers you give will play a part in understanding more
about the overall health of Georgia citizens. The information will contribute valuable information to
research.
The survey is private and your participation is voluntary; taking the survey means you consent to take
part in the study. The answers will not be traced to you, so please give honest answers to each question.
Thank you.
For the purposes of this survey, we are asking about the quadrivalent HPV vaccine (Gardasil®).

1.

How often do you use the following sources to obtain information about the HPV vaccine?
Never
Rarely
Sometimes
Often
Always

Professional
Organizations (e.g.,
AAFP, ACOG, AAP,
SGIM)
Advisory Council on
Immunization Practices
(ACIP)
State and local
immunization
Programs
Colleagues
Pharmaceutical
representative
Internet websites
Media
Medical conferences
Grand rounds/local
institutional lectures
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2.

Please answer the following true/false questions and base your answers on your current
understanding of HPV and HPV vaccine, without looking at other sources of information. Feel free
to check ”Unsure” when you do not know the answer. (Please check box that applies for each
statement.
True

Most HPV infections resolve without medical intervention.
HPV is a relatively uncommon sexually transmitted infection.
HPV causes genital warts in males and females.
Almost all cervical cancers are caused by HPV infection.
The FDA approved the quadrivalent HPV vaccine for use in
females ages 9-26.
Females who have been diagnosed with HPV infection should
not be given the HPV vaccine.
The FDA approved the quadrivalent HPV vaccine for use in
males for permissive use for ages 9-26.

Please go to next section
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False









Unsure









3.

How strongly would you agree or disagree that the following are barriers related to immunizing your
patients against HPV?
Strongly
Disagree

My concerns about the
safety of HPV vaccine
My concerns about the
efficacy of HPV vaccine
Administering a new
vaccine with a limited
track record of safety
Adding another vaccine
to the vaccine schedule
Lack of information
about the quadrivalent
HPV vaccine
The upfront cost of
purchasing private stock
HPV vaccine to my
practice
The cost of stocking HPV
vaccine
Lack of adequate
reimbursement for HPV
vaccination
Failure of some insurance
companies to cover the
cost of vaccination
The time it takes to
discuss HPV vaccination
with patients and /or
parents
Difficulty ensuring that
patients will complete the
3-dose HPV vaccination
series
HPV vaccination is not
required for school
attendance

Somewhat
Disagree

Neutral

Somewhat
Agree

Strongly
Agree















































































































Please go to next section
129

4.

How often have you experienced the following parental barriers to immunizing female patients
against HPV?
Check here if you don’t recommend HPV vaccine in your clinic practice and skip to
Question 9
Never
0%

Parent concern about
vaccine Safety
Parent concern about
vaccine efficacy
Parent reluctance to
discuss
sexuality/sexually
transmitted infections
Parent concern that
adolescent will assume
that a parent who agrees
to HPV vaccination
condones premarital sex
Parent concern
vaccinated child will
practice riskier sexual
behaviors
Lack of parent
education/understanding
about HPV infection
Parent requests that
HPV vaccination be
deferred
Parent believes child is
not at risk for HPV
infection
Parent won’t consent to
vaccination
Parent opposition to
HPV vaccination for
moral or religious
reasons
Parent believes child is
too young for the HPV
vaccine
Parent concern about
negative media reports
related to the HPV
vaccine

Rarely
1-25%

Sometimes
26-50%

Often
51-75%

Always
>75%
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5.

In the past 12 months, how often did you recommend the HPV vaccine to your female
patients, in the following age groups:

Never
0%
Ages 9-10
Ages 11-12
Ages 13-17
Ages 18-26

6.






Rarely
1-25%

Sometimes
26-50%

Often
51-75%

Always
>75%





















Do not see
patients in
this age
group






In the past 12 months, how often did you administer at least one does of the HPV vaccine to your female
patients, in the following age groups:

Never
0%
Ages 9-10
Ages 11-12
Ages 13-17
Ages 18-26






Rarely
1-25%

Sometimes
26-50%
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Often
51-75%






Always
>75%






Do not see
patients in
this
age group






7.

In the past 12 months, how often did your female patients or parents of your female
patients in the following age groups refuse HPV vaccination (i.e., did not agree to vaccination
currently or at a later date)?

Never
0%
Ages 9- 10
Ages 11- 12
Ages 13- 17
Ages 18- 26

8.

Sometimes
26-50%

Rarely
1-25%











Often
51-75%






Do not see
patients in
this
age group

Always
>75%
















The ACIP has recommended optional HPV vaccination for boys and young men to protect them from
genital warts, although the ACIP stopped short of recommending its routine use in boys. How often
would you recommend vaccination to males in the following age groups:

Never
0%
Ages 9- 10
Ages 11- 12
Ages 13- 17
Ages 18- 26






Rarely
1-25%

Sometimes
26-50%






Often
51-75%











Always
>75%






Do not see
patients in
this
age group






The remaining questions are included so that we will know about the physicians reached by this
survey and the characteristics of their practices.
9.

Are you a Vaccine for Children (VFC) provider?
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Yes

No

Don’t know

10. Which of the following describes your primary clinical specialty? (choose one)

 Pediatrics
 Family Medicine
 Internal Medicine

 Obstetrics/Gynecology
 Other (Specify): _____________________
 Academic

11. Including you, how many physicians are in your practice setting?

 1  2-5  6-9  10-14

 15 -25  26-49

 50+

12. Which of the following best characterizes your practice situation?

 Single Specialty  Multispecialty  Other (Specify)
13. About what percent of your patients use the following primary payment methods?
(Please approximate; groups may not sum up to 100%)
0%
Private insurance
Medicaid
PeachCare (Georgia’s Children’s Health
Insurance Program (CHIP)
Uninsured/self-pay
Medicare
Other

1-25%

51-75%

76-100%
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26-50%

14. Compared to my clinical peers, I am often among the first to use a newly recommended
vaccine.
Strongly
Disagree

Somewhat
Disagree





Neutral



Somewhat
Agree

Strongly
Agree





15. I tend to wait to adopt new medications, vaccines, or procedures until I hear about them
from several trusted colleagues.
Strongly
Disagree

Somewhat
Disagree





Neutral



Somewhat
Agree

Strongly
Agree





16. Which of the following best describes the geographic location of your clinical practice?

 Urban
 Suburban

 Rural
 Other (Specify): _____________________

17. What is your age?

18.

Are you:





Male

years

 Female

19. Which term best describes your race/ethnic group?

 White/Caucasian
 Asian
 Native Hawaiian/Pacific Islander
 Other






Black/African-American
American Indian/Alaska Native
Mixed race
Prefer not to answer

Please go to next section
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20. Are you Hispanic or Latino?

 Yes

 No

21. In what year did you complete residency training?



22. In what zip code is your primary practice located?



23.

Date survey completed: mm/dd/yyyy

 /  / 

Do you have and additional comments or suggestions that apply to the HPV vaccine from your
perspective that you are willing to share?

This is the end of the survey. Thank you for your time

End of Survey

135

E. First Email to Physicians
(First email sent to MD offices informing MD of upcoming survey)

Good Afternoon! I am a public health nurse and a doctoral candidate at Georgia Southern
University in the College of Public Health. Your medical practice was selected as part of a
statistical sample of physician practices in Georgia to take part in a survey pertaining to the
quadrivalent HPV vaccine, Gardasil® .
I hope you will find the time to complete the survey when it is sent to this office. The entire
process will take less than 10 minutes. The 23 item survey is to obtain information on Georgia
physician knowledge, barriers, and ACIP practice as it pertains to the HPV vaccine, Gardasil® .
The information will add to the current knowledge of immunization practice in Georgia. A
similar survey was conducted in Texas and Florida. This study has been approved by the Georgia
Southern University Institutional Review Board. To decrease the amount of time this takes, only
one physician (or his/her representative) is requested to complete the survey regardless of how
many physicians practice at this location.
I will send a second e-mail instructing you how to access the survey online. If there is someone
else in this office who should receive this e-mail, please let me know by return e-mail and I will
make the correction. If you request, I can send the survey by postal mail with a return postage
paid envelope. As you can see, I am doing what I can to decrease the amount of time you spend
on the survey. Please know all responses will be held confidential. For every survey completed,
$1 will be donated to the American Cancer Society.
Thank you very much for your time, I know it is valuable.
Elizabeth Dixon, RN, BSN
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F. Second Email with Internet Link
Good Day,
I am a public health nurse and a doctoral student at Georgia Southern University in Statesboro
Georgia in the college of Public Health. Your medical practice has been selected to take part in a
survey pertaining to the quadrivalent HPV vaccine, Gardasil® . The survey is confidential and
has been approved by the Georgia Southern University Institutional Review Board.
Here is a link to the survey.
This link is uniquely tied to this survey and your email address. Please do not forward this
message. Only one physician (or his/her representative or nurse) is requested to complete the
online survey regardless of how many physicians practice at this location. If a nurse or physician
representative completes the survey on behalf of the physician, please respond as if you are the
physician. For example, there is a question “in what year did you complete residency training?”
Please respond with the answer that represents the year the physician completed his/her
residency, rather than the year you completed your training.
I hope you will find the time to complete the enclosed survey. The entire process will take less
than 10 minutes. The 23 item survey is to obtain information on Georgia physician knowledge,
barriers, and ACIP practice as it pertains to the HPV vaccine, Gardasil® . The information will
add to the current knowledge of immunization practice in Georgia. A similar survey was
conducted in Texas and Florida.
Thank you very much for your time. If you have any questions or concerns, I may be reached by
phone at 912-898-1222 or by email at ed00027@georgiasouthern.edu. Please know all responses
will be held confidential. For every survey completed, $1 will be donated to the American
Cancer Society.
Sincerely,
Elizabeth T. Dixon, RN, BSN

Please note: If you do not wish to receive further emails from us, please click here, and you will
be automatically removed from our mailing list.
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G. Postal Mail Survey
(For those who did not have email address or who had not responded to email survey)
Good Morning,

I am a public health nurse and a doctoral student at Georgia Southern University in
Statesboro Georgia. Your medical practice has been selected to take part in a survey
pertaining to the quadrivalent HPV vaccine, Gardasil® . The survey is confidential and has
been approved by the Georgia Southern University Institutional Review Board.
Only one physician (or his/her representative) is requested to complete the enclosed survey
regardless of how many physicians practice at this location. If a nurse or physician
representative completes the survey on behalf of the physician, please respond as if you are
the physician. For example, there is a question “in what year did you complete residency
training?” Please respond with the answer that represents the year the physician
completed his/her residency, rather than the year you completed your training.
I hope you will find the time to complete the enclosed survey. The entire process will take
less than 10 minutes. The 23 item survey is to obtain information on Georgia physician
knowledge, barriers, and ACIP practice as it pertains to the HPV vaccine, Gardasil® . The
information will add to the current knowledge of immunization practice in Georgia. A
similar survey was conducted in Texas and Florida.
Thank you very much for your time. If you have any questions or concerns, I may be
reached by phone at 912-898-1222 or by email at ed00027@georgiasouthern.edu. Please
know all responses will be held confidential. For every survey completed, $1 will be
donated to the American Cancer Society.
Sincerely,

Elizabeth T. Dixon, RN, BSN
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H. Follow Up Phone Call
(left on voice mail or with physician answering service)

Hello, [KEY INFORMANT NAME]!
My name is Elizabeth Dixon I am doing my dissertation research at Georgia
Southern University on the quadrivalent HPV vaccine - Gardasil.
I am calling because this Medical Practice was selected from a random sample of
all Georgia practices that provide immunizations to their patients.
Your help is needed as a participant in this study. By now this office should have
received a (MAIL OR EMAIL) survey. The survey is an assessment of HPV
vaccination knowledge, barriers, and practice guidelines.
Questions on this survey have been used in Texas, Florida and other states and are
designed to match up with the most current guidelines and recommendations
published by the Advisory Committee of Immunization Practice.
The 23-item survey should take no more than 10 minutes to complete. All
responses will be held confidential; for your information, this study has been
approved by the IRB at GSU and will contribute valuable information to research
on immunization practice in Georgia.
Your participation is very much appreciated and I hope you will take the time to
complete the survey.
If you have not received the survey or would like to have it resent to your office,
please call 912-898-1222 or you may request by email at
ed00027@georgisouthern.edu.
Thank you.

139

I. Follow up Phone Call (during office hours)

Hello, [KEY INFORMANT NAME]!
My name is Elizabeth Dixon I am doing my dissertation research at Georgia
Southern University on the quadrivalent HPV vaccine - Gardasil.
I am calling you again because your Medical Practice was selected from a random
sample of all Georgia practices that provide immunizations to their patients.
Your help is needed as a participant in this study. By now your office has received
two or three (MAIL OR EMAIL) surveys. The survey is an assessment of HPV
vaccination knowledge, barriers, and practice guidelines.
The 23-item survey should take no more than 10 minutes to complete. All
responses are confidential. This study has been approved by the IRB at GSU and
will contribute valuable information to research on immunization practice in
Georgia.
Do you have the time now, or should I call back? When is a good time for me to
call back?
(survey by phone) If you have a few minutes, we can do the survey now!
That’s it. Your participation is very much appreciated! Thank you again for the
time you took away from your practice and with me to answer these questions.
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